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Abstract

E-CIGARETTES AND SMOKING CESSATION: ECONOMIC IMPACT ON CURRENT
SMOKERS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
By Anal Shah, MS, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Advisor: David Holdford, PhD Professor, Department of Pharmacotherapy and
Outcomes Science

Introduction:
Awareness and usage of Electronic cigarettes (e-cigs) among smokers have increased
rapidly over the past few years, majorly in quitting smoking. The main objectives for this
study were: 1) To estimate the prevalence and study sociodemographic predictors for
e-cigs use among individuals with Chronic Obstructive Pulmonary Disease (COPD). 2)
To examine the predictors and estimate the total healthcare costs among current
smokers with COPD. 3) To estimate the economic impact of adopting e-cigs as a
smoking cessation tool among smokers with COPD.
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Methods:
The National Health Interview Survey data from the year 2014 was utilized to estimate
the prevalence and identify sociodemographic predictors associated with e-cigs use
among COPD adult population. Total healthcare costs and sociodemographic and
clinical predictors among current smokers with COPD were estimated using the Medical
Expenditure Panel Survey data from the year 2012-2013.
Economic impact for adoption of e-cigs was obtained by developing an epidemiological
cohort-Markov model from a societal perspective over the period of 5-year. The targeted
population was smokers with COPD and willing to quit smoking. Smoking abstinence for
e-cigs was compared with Varenicline, Bupropion, and Nicotine Replacement therapy.
Outcomes evaluated were the 1-year and accumulated 5-year total healthcare costs
savings associated with e-cigs over other options.
Results:
Among individuals with COPD, 8.65% and 24.37% were current and ever e-cig users
respectively. Current e-cigs use was found to be associated with individuals who have
tried quitting smoking in the past (OR: 2.0; 95%CI: 1.05, 3.97). Adjusted total healthcare
costs per patient/year among smokers with COPD were found to be higher by $1,811 in
comparison to non-smokers with COPD. The adoption of e-cigs among COPD smokers
can have a positive impact on the healthcare budget and can lead to healthcare cost
savings of $37.71 million over the period of 5-year. Furthermore, a positive impact on
budget were found among women and individuals with age 65 & above.

xvi

Conclusion:
E-cigs may be beneficial to the current US healthcare system if adopted as a smoking
cessation tool among COPD individuals. However, uncertainty associated with product
safety, efficacy and adherence for cessation warrants further studies and evaluation.

Chapter 1: Introduction
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease arising
due to obstruction in the lung airways that can result into having shortness of breath and
cough as its chief symptoms.1 It is mainly characterized as having emphysema and
chronic bronchitis and in some conditions it includes asthma as well.2 Emphysema,
categorized as a type A COPD, is a diease of the lung wherein alveolis that are
responsible for the exchange of carbon dioxide and oxygen are damaged resulting into
the loss of lung tissue functioning.3 This can lead to experiencing shortness of breath,
having cough and wheezing. In the majority of people, symptoms of emphysema
progress slowly.4 Chronic bronchitis, categorized as a type B COPD, is a lung disease
arising due to an inflammation of the lung airways leading to the development of cough,
that can last anywhere from 3 months to 2 years in a row, along with the frequent
manifestation of viral and bacterial infections.2,3 Other common symptoms for an
individual with COPD involves experiencing chest tightness, fatigue, and a chronic
cough. These symptoms gets worse over time where patients can experience muscle
loss, can have morning headaches, or can develop bluish or greyish color below the
fingernails due to less supply of oxygen levels in the blood.5 Treatment for COPD will
depend on the condition and severity of the disease and treatment choices will involve
the use of medications such as long- or short-acting bronchodilators, steroids,
antibiotics, along with using other treatment options such as oxygen therapy,
pulomonary rehabilitation program, or performing surgeries such as lung volume
reduction, doing lung transplant or bullectomy.6
17

According to the Global Initiative for Chronic Obstructive Lung Disease, it defines COPD
into four different stages on the basis of spirometry results from the lung fuction test. 7
This test estimates the amount of air an individual can blow out in one second, also
known as Forced Expiratory Volume (FEV 1). Table 1 below depicts different stages for
COPD according to the FEV1 levels. As an individual progresses towards different
stages of COPD, breathing and airflow becomes more dififcult. COPD staging can help
patients to better understand their disease condition and predict life expectancy, while
for physicians it can help them make better treatment recommendations.7
Table 1: COPD staging by GOLD classification and FEV1 levels
GOLD stages7

COPD term

FEV1 levels

Stage I

Mild COPD

FEV1≥ 80% normal

Stage II

Moderate COPD

FEV1 50-79% normal

Stage III

Severe COPD

FEV1 30-49% normal

Stage IV

Very Severe COPD

FEV1 <30% normal, or <50% normal
with chronic respiratory failure
present

COPD epidemiological facts

In 2004, 3 million deaths occurred globally due to COPD where 90% of them were from
low and middle income countries.8 World Health Organization (WHO) has projected
COPD to be the third most leading cause of death by 2030.8 Global burden for COPD is
expected to increase in future years due to a globally aging population and a continuous
exposure to risk factors such as air pollution and smoke.9,10 In the United States, the
18

Centers for Disease Control and Prevention (CDC) ranked COPD as the third most
leading cause of death and disability in 2014.11 Nearly 15 million US adults were
diagnosed with COPD in 2014 and prevalence was found to be varying by state.
Despite such high prevalence, it remains undiagnosed or untreated in nearly half of the
patient population.12 COPD rates were found to be higher in individuals over age the
age of 65 years, in women, in non-Hispanic white population, those who are
unemployed, divorced, widowed or separated, are current or former smokers and have
the history of asthma.11
COPD and economic burden

COPD is a major driver of avoidable healthcare costs.13 It causes long-term disability,
early deaths and is an important issue affecting employees health and workproductivity.14,15 In 2010, the National Heart, Lung, and Blood institute estimated direct
healthcare costs due to COPD as $29.5 billion, where $13.2 billion accounted for
hospital care costs, $5.5 billion were for physician services and $5.8 billion were for
prescription drugs.16 The indirect costs was around $20 billion and the number of
productive days lost due to suffering from COPD was higher than any other chronic
conditions.17,18 An adult with COPD spends on an average $6,000 more to healthcare
than an adult without COPD.19 Healthcare costs also vary by COPD severity stages as
an individual in later stage incurs higher medical costs than an individual with COPD in
an early stage. The average per patient per year direct cost for patients with stage I,
stage II and stage III COPD were $1681, $5037 and $10,812 respectively.20
Hospitalization was identified as one of the most significant and contributing cost
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variable for all the stages of COPD. By the year 2020, CDC has projected that medical
care costs for COPD will be higher than $90 billion signifying a substantial and a
significant economic burden to the individuals and society.21
COPD and Smoking

Several risk factors responsible for the development and progression of COPD include
tobacco smoke, air pollutants, occupational dusts and chemicals, genetics, history of
childhood respiratory infections, socio-economic status and exposure to second hand
smoke (SHS).22 However, the key factor responsible for the development of this disease
is smoking tobacco where for all those individuals who have been diagnosed with
COPD, almost 90% of them have smoked tobacco.23 Tobacco smokers are nearly 12 to
13 times at higher risk of death from COPD than those who are non-smokers.24
Individuals with a family history of COPD are at a higher risk to develop this disease if
they smoke tobacco.

Tobacco smoking itself is the single largest preventable cause of disease and death in
the United States leading to more than 480,000 deaths every year and more than
41,000 of these deaths are due to second hand smoke (SHS) exposure.25 In 2014, an
estimated 40 million US adults aged 18 years or older were current smokers. 26
Prevalence of current smokers differs by age and gender. The percentage of people
who were current smokers was found to be higher in working adult population aged 1864 years (54.7%) in comparison to those with age 65 and over (8.5%). Similarly,
prevalence of current smoking was higher in males (18.8%) in comparison to females
(14.8%) in the US for the same year.25 Tobacco smokers are 2-4 times at a higher risk
20

to develop coronary heart disease, 2-4 times at a higher risk to develop stroke and
nearly 25 times at a higher risk to develop lung cancer. It affects overall health,
increases absenteeism from work and possess higher healthcare utilization and cost.27
Annual healthcare spending attributable to such smoking-related illness in adults was
more than $300 billion per year, which includes $170 billion in direct medical care cost
and $156 billion for productivity loss. Hence, COPD patient population who are
currently smoking tobacco possess not just high medical direct and indirect healthcare
costs but are also at a higher risk to develop other smoking-related illness which can yet
again have a huge economic burden to the individuals and the society.28 In order to
lower such high medical care cost and sufferings due to COPD and smoking-related
illness, clinicians are highly recommended to use the interventions that can help prevent
tobacco smoking and can reduce clinical complications due to COPD, while patients are
recommended not to smoke and seek medical advice from physicians for quitting
tobacco smoke.29

COPD and Smoking Cessation
Several methods are utilized or recommended to help quit tobacco smoking. They
include the use of either cold-turkey, behavioral counseling, Nicotine Replacement
Therapy (NRT’s), prescribed medications such as Varenicline, Bupropion, or using the
combination treatments which includes the mix of behavioral counseling along with
prescribed medications.29 Amongst alternatives, the most frequently utilized and
recommended are prescribed medications such as Varenicline or Bupropion, or over the
counter medications such as NRT’s.30 However, these products have relatively less
consumer attraction and product satisfaction.30,31 Possible reasons could be due to the
21

side effects associated with the use of these medicinal products. Other plausible
reasons are medication costs, difficulty in adhering to the medications prescribed, and
costs of seeing physician to receive a prescription.
E-cigarettes and Smoking Cessation
Electronic cigarettes (e-cigs), also known as electronic nicotine delivery system (ENDS),
are battery operated devices that deliver nicotine to the users by heating a solution of
nicotine, propylene glycol or glycerin, and flavoring agents into a gas for inhalation.32
These devices were introduced into the US market in the year 2007 as an alternative to
conventional tobacco smoke.33 They are manufactured to resemble tobacco cigarettes
and are available with more than 500 different brands and 7700 unique flavors. 34 Most
e-cig devices a made of a cartridge, a heating device and a power source.32 Currently,
four generations of e-cig devices are available in the market and each of them differs
with respect to the device size and shape.32 As these devices resemble conventional
tobacco cigarettes in its aesthetics, they are thought to simulate the behavioral
experience of tobacco smoking. In addition, they deliver nicotine without the harmful
chemicals and tar emitted by regular tobacco cigarettes.32 Since the introduction of
these devices into the US market, their sales have grown (almost $1.5 billion dollars per
year) and it is estimated that the sales may continue to rise by 24.4% per year until
2018.35,36 These devices are marketed direct to consumers via television, internet and
print advertisements as a healthier substitutes to tobacco smoke.37
The CDC reported that the use of these devices among US adults has increased over
years.38 In 2014, prevalence of e-cig users among the US working adult population was
found to be 3.8% (5.5 million of 146 million people), where nearly 16.2% of these
22

estimates were current cigarette smokers.38 In another study done by McMillen et al.,
which assessed four year trends in e-cigs use among the US adults between the years
2010 and 2013, percentages of people who were ever e-cig users increased from 1.8%
to 13% while for current e-cig users these estimates increased significantly from 0.3% to
6.8%.39 Recently, a new trend to consume these devices to quit tobacco smoking has
been found where smokers are finding these devices helpful in helping them to quit
smoking and are preferred more over medicinal products that are currently available in
the market for smoking cessation.40,41 A household survey amongst US current smokers
done in June 2011 had 70% of the respondents reporting to use e-cigs for helping them
to quit smoking.35 Several clinical trials and systematic literature reviews have been
published with the mixed results for its evidence related to efficacy of e-cigarettes use in
smoking cessation amongst current smokers.42,43,44,45,46
The use of e-cigs for smoking cessation is controversial amongst health experts where
some question whether these devices are helping smokers in quit or whether they just
serve as a gateway to start smoking. Experts in the UK are open promote the use of
these e-cigs to help smokers in quitting, while experts in the US are less enthusiastic
due to concerns about encouraging tobacco use among the younger population.47,48
E-cigarettes and the U.S. regulations
E-cigs were unregulated in the United States until May 5 th, 2016, where the US FDA
announced a ban on sales to anyone under age 18.49,50 Also, adults under 26 years are
required to show their photo-id before making a purchase. In addition, e-cig producers
will now be required to go through a lengthy registration and safety review process with
the FDA to get their product approved along with other regulatory requirements such as
23

providing them product ingredient details (including potentially harmful additives),
manufacturing process and evidence that the product is safe to consume. Any e-cig
devices with different flavors will have to be registered seperately as a new product and
this regulation applies to all vape shops as well that sell e-cigs with their own unique
product flavors.49 Producers will have to get FDA approval for their products first before
marketing them with any product labels that can claim as mild or light. Producers will
also be restricted from giving out free samples for promotion. All e-cig manufacturers
are expected to have registered with the FDA by August 8th, 2016. They will have up to
2 years to sell their products while preparing for their FDA applications, and up to 1
additional year till FDA reviews their submitted application.49
Health experts believe that this law can either lay a new generation to the use of
traditional cigarettes or can reduce the number of current smokers trying to use this
device for quiting smoking.51,52 Furthermore, it is also believed that this new law is
going to be tough for small producers as it will be challenging for them to meet the FDA
deadlines for product registration along with the expenses that comes around with the
litigation process. According to the American Vaping Association, new regulations will
be prohibitively expensive to small producers as submitting a new application could take
somewhere around 1700 hours and more than $1 million dollars.53,54 Despite this new
regulation, manufacturers and proponents are actively promoting e-cig products for its
use in smoking cessation through paid press releases and online via social media
through Facebook, Twitter, and YouTube.37 Some promote misleading claims regarding
the effectiveness of their devices.37 Others target pregnant women by claiming that use
of e-cigs in pregnancy is safer and healthier than conventional tobacco products.54 The
24

lack of evidence about effectiveness and safety of e-cigs has led the US government be
cautious in supporting its use in smoking cessation.
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Chapter 2: Literature review
2.1: Literature Review
Tobacco use is a major risk factor in the development of chronic diseases such as
cancer, stroke, heart disease, lung diseases, COPD, and diabetes. It can harm almost
every organ of the body.25 Nevertheless, its use is common throughout the world.
Global deaths due to use of tobacco are nearly 6 million per year; projected to rise to 8
million deaths per year by 2030.55 It is a major cause of preventable death, where those
who smoke live 10 years less on average than those who do not smoke.56 Quitting
smoking is associated with significant health benefits.55
Several therapies are available in the market for smokers to help them in reducing or
quitting tobacco use. The United States Public Health Service recommends the use of
first-line pharmacotherapies such as nicotine replacement therapy (NRT), Bupropion,
and Varenicline for smoking cessation.57 These therapies have established safety and
efficacy profile to treat tobacco dependence and are approved by US-FDA for cessation
of smoking. These pharmacological aids make it easier for a smoker to quit the use of
tobacco by helping users in reducing the symptoms of nicotine withdrawal. 57
Bupropion was approved by the US FDA in 1997 as a smoking cessation
pharmacotherapy drug that is available only by prescription.58 It exerts its main effect
through blocking the reuptake of dopamine and noradrenaline along with the presence
of little serotonergic effect. It is available as an extended release anti-depressant pill
that helps in reducing symptoms associated with nicotine withdrawal. Treatment
duration for such therapy can be anytime between 7-weeks and 12- weeks.58
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In 2006, the US FDA approved another prescription pharmacotherapy Varenicline
tartrate (available as Chantix) for its use in smoking cessation for the course of 12weeks.59 It is a partial agonist at the alpha-4 beta-2 subunit of the nicotine acetylcholine
receptor where by binding to this receptor it helps in reducing symptoms associated with
nicotine withdrawal. It also blocks nicotine from the smoke to bind with this receptor and
thereby it reduces the dependence to nicotine. This drug is very well tolerated, has
better efficacy profile and hence makes it a valuable option among smokers for quitting
smoking.59
Currently, there are three different Nicotine Replacement Therapies (NRT’s) available in
the US market as over the counter (OTC) medications.60 These include lozenges,
chewing gum and transdermal patches. NRT’s deliver nicotine at the sub-optimal level
in the brain above which is associated with withdrawal. Hence it helps smokers in
overcoming nicotine withdrawal symptoms. Long-acting Nicotine patches are prescribed
primarily to control long-term abstinence, while rapidly-acting Nicotine lozenges/gums
are provided to help relieve rapid acute cravings and withdrawal symptoms. The choice
for this rapid-acting will depend on patient comorbidities and their preferences. Overall,
these products are considered to be safe for patients and are used more commonly
among other available alternatives for quitting smoking.60
Despite the availability of these pharmacotherapies that have shown great clinical
response to achieving smoking cessation, these treatments however lack the behaviour
and sensory aspects of smoking among smokers wanting to quit.40 E-cigarettes address
this limitation along with offering a novel approach to smokers to use these devices for
cessation. E-cigs can deliver a dose of nicotine that can be decreased gradually to a
27

placebo level, and can provide satisfaction to the smokers as it mimics smoking
behaviour. They are cheaper than regular tobacco, can be used for long-term and can
provide nicotine without involving those 7000 chemicals that are known to have cause
cancer.41 Several studies have tried to evaluate the effect of these devices in smoking
cessation over short and long-term along with the evaluation of side effects.
Hence, a comprehensive literature search of MEDLINE through PubMed and Google
Scholar was performed to review articles that analyzes the effect of e-cigarettes in
smoking cessation for a minimum period of 6-months. Search terms used were
[“Electronic cigarettes” OR “e-cigarette” OR “e-cigs” OR “Electronic nicotine delivery”]
AND [“Smoking cessation” OR “Quit smoking” OR
“Smoking abstinence” OR “Smoking reduction”]. Cited articles were retrieved from the
original articles to include additional research articles. Articles that were included for
review were the ones that were conducted in humans, among adults currently smoking,
have investigated smoking cessation or abstinence as a primary outcome, outcomes
that were measured for at least 6-months, published in English and with the study
design as randomized controlled trials, cross-sectional studies, cohort studies or casecontrol studies.
On the basis of this search criteria, 19 studies were found that evaluated the effect of ecigarettes for its use in smoking cessation for the minimum period of 6-months. Table 2
summarizes them all on the basis of study design, sample size included, participants
characteristics, study intervention and smoking cessation outcome.
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Table 2: Literature review articles – E-cigs & Smoking Cessation
Source

Study participants

Randomized controlled trial
Bullen et
Current smokers from Auckland,
al. 2013
New Zealand, 18 years and older,
(ASCEND
with the intention to quit smoking
trial)42

Sample
size

Intervention vs. comparator

657

Three groups compared parallel:
Group A:B:C: 16 mg nicotine ecigs; 21 mg nicotine patch;
placebo e-cigs

Current smokers from Catania,
Italy, between 18 and 70 years
older, with the intention to quit
smoking

300

Three groups compared parallel:
Group A:B:C: 7.2 mg nicotine ecigs; 7.2 + 5.4 mg nicotine e-cigs;
placebo e-cigs

Adriaens et Current smokers from Leuven,
al. 201461
Belgian, not intending to quit
smoking

51

Three groups compared parallel:
Group A received the Joyetech eGO-C second-generation e-cigs;
group B received the Kanger T2CC second-generation e-cigs,
while group C received no
treatment at baseline. For both
groups; A and B, participants were
provided 30 ml bottles of tobaccoflavored e-liquid with 18mg/ml of
nicotine

Caponnetto
et al. 2013
(ECLAT
trial)43

Prospective cohort study with intervention
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Smoking cessation outcome

Verified continuous smoking
abstinence rate at 6 months:
7.3% (group A) vs. 5.8% (group
B) vs. 4.1 %( group C).
≥ 50% reduction in cigs
smoked/day at 6 months: 57%
(group A) vs. 41% (group B) vs.
45 %( group C).
Verified continuous smoking
abstinence rate at 12 months:
13% (group A) vs. 9% (group B)
vs. 4 %( group C).
≥ 50% reduction in cigs
smoked/day at 6 months: 13%
(group A) vs. 9% (group B) vs. 4
%( group C).
Verified continuous smoking
abstinence rate at 8 months: 19%
(total for both group A and B) vs.
25% (group C).
Combined smoking reduction and
smoking abstinence among e-cig
users at 8-months: 44%

Polosa et
al. 201162

Regular smokers, 18-60 years
old, from Catania, Italy, not
intending to quit smoking

40

Participants were invited to use
popular e-cig brand containing 7.4
mg nicotine as its dose strength

Caponnetto Regular smokers with
et al.201363 schizophrenia, from Catania,
Italy, not intending to quit
smoking,

14

Participants were invited to use
popular e-cig brand containing 7.4
mg nicotine as its dose strength

Ely J et al.
201364

Current smokers, residing in
Moffat county, Colorado,
motivated to quit

44

Polosa et
al. 2014i65

Regular smokers, from Catania,
Italy, not intending to quit
smoking

40

Provided structured smoking
cessation program for 6-months
which was based on the ‘5As’ and
the transtheoretical model to treat
tobacco use and dependence
Participants were invited to use
popular e-cig brand containing 7.4
mg nicotine as its dose strength

Polosa et
al. 2014ii66

Regular smokers, 18-60 years
old, from Catania, Italy, not
intending to quit smoking

50

Pacifici et
al. 201567

Current adult smokers, 18-63
years old, not intending to quit
smoking, have never tried quitting
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Self-reported continuous smoking
abstinence rate at 6-, 18- and 24months: 23%, 15% and 13%
respectively.
≥ 50% and ≥80% reduction in
cigs smoked/day at 6 months:
32.5% and 12.5% respectively
Self-reported continuous smoking
abstinence rate at 12-months:
14.3%.
≥ 50% reduction in cigs
smoked/day at 12 months: 50%
Self-reported continuous smoking
abstinence rate at 6 months: 44%

Self-reported continuous smoking
abstinence rate at 24 months:
12.5%
≥ 50% reduction in cigs
smoked/day at 6, 18 and 24
months: 25%, 27.5% and 27.5%
respectively
≥ 80% reduction in cigs
smoked/day at 6, 18 and 24
months: 1%, 7.5% and 15%
respectively
Participants were invited to use
Self-reported continuous smoking
popular e-cig brand containing 9
abstinence rate at 6 months: 36%
mg/ml nicotine as its dose strength ≥ 50% and ≥80% reduction in
cigs smoked/day at week-24:
30% and 14% respectively
Provided commercially available e- Self-reported continuous smoking
cigs device. Medical training and
abstinence rate at 12 months:
assistance for e-cigs use were also 53%
30

Polosa et
al. 201568

tobacco use, never tried any
smoking cessation therapies
Adult smokers (≥ 18), making first
purchase at participating local
vape shop in Catania, Italy

Prospective cohort study with no intervention
Etter et al.
Longitudinal online survey among
201444
participants registered online, age
18 and over, have provided their
email address for follow-up, daily
e-cig users. Participants
registered were from US, UK,
France, Switzerland, and other
countries.
Grana et al. Longitudinal online survey among
201469
current smokers, recruited
through Knowledge network
panel, have used e-cigs in past 3days even once
Borderud
SP et al.
201470

Prochaska
et al. 201471
Choi et al.
201472

Current smokers, diagnosed with
cancer, referred to the Tobacco
Treatment Program at Memorial
Sloan-Kettering Cancer Center,
New York, using e-cig devices
within 30-days prior to enrollment,
motivated to quit
Adult current smokers, not
motivated to quit tobacco, using
e-cigs at baseline
Young adults, currently smoking,
residing in Minnesota, never used

71

provided along with behavioral
support
Participants motivated to use ecigs along with providing
instructions on e-cigs use

Self-reported continuous smoking
abstinence rate at 6- and 12months: 42% and 41%
respectively
Aggregated smoking reduction
and abstinence at 12-months:
66.2%

773

--

Complete self-reported cessation
at 1- and 12-months: 22% and
46% respectively
Reduction in daily cigs smoked
per day at 12-months: 10.5

949

--

Complete self-reported cessation
at 12-months among regular
smokers with and without e-cig
use at baseline: 10% (9/88) and
14% (119/861) respectively.

1074

--

Complete self-reported cessation
at 12-months: 14.5%

956

--

Complete self-reported cessation
at 12-months: 21%

1379

--

Complete self-reported cessation
at 12-months: 11%
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e-cigs at baseline, able to followup at 1-year,
Brown et
Current smokers, ≥ 18 years,
al. 201445
smoked in past year, made at
least one quit attempt either with
e-cigs or NRT’s or without any
aids.
Brose LS et Web-based online survey among
al. 201573
current smokers, recruited
through Ispos MORI, have used
e-cigs at baseline
Al-Delaimy Telephone based survey among
et al. 201574 California smokers, between 18
and 59 years old, have used ecigs at both baseline and followup, with the intention to quit
smoking
Manzoli et
Current smokers, between 30
al. 201575
and 75 years of age, used any
type of e-cigs and inhaling at
least 50 puffs weekly for past 6months, or dual users

5863

Self-reported nonsmoking at > 26
weeks for e-cigs, NRT’s and
without any aid: 19.1%, 8.4% and
16.7% respectively

4064

1012
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--

Complete self-reported cessation
at 12-months: 8%
% attempted to quit in past 1
year: 46%

--

Complete self-reported cessation
at 12-months among ever e-cig
users and among never e-cig
users: 5% and 10.5%
respectively

--

Complete self-reported cessation
at 12-months: 16% (51/319)

Randomized controlled trial
Caponnetto et al. 2013 42
Caponnetto et al. conducted the first randomized controlled trial ECLAT to study the
efficacy and safety of electronic cigarettes. This study was a prospective, 12-month
double-blind, randomized, controlled trial to evaluate smoking reduction, smoking
abstinence and adverse effects among smokers not intending to quit smoking. Study
participants recruited for this study were regular smokers from Catania (Italy) smoking ≥
10 cigarettes per day, between 18 and 70 years old and in general good health.
Participants were randomized into three groups on the basis of two different nicotine
strengths of e-cigarettes: Group A (n = 100) received 12 weeks supply of 7.2 mg
nictoine cartridge; Group B (n = 100) received two 6-week supplies of nicotine
cartridge: first 6-weeks for 7.2 mg nicotine cartrdige and for the next 6-weeks reciveing
a supply of 5.4 mg nicotine cartridge; Group C (n = 100) receiving 12 weeks supply of
e-cig cartridges with no nicotine in it. The most popular electtronic cigarettes brand
‘Categoria’ was utilized for this study. Study outcomes evaluated were smoking
reduction (number of cigarettes smoked/day) and smoking abstinence (exhaled carbon
monoxide (eCO) level; concentration of ≤ 7 ppm).
During each study visit, significant differences were observed in all three study groups
when compared to its baseline(P < 0.001). However, no significant differences were
observed among three study groups. With the intention to treat analysis and excluding
quitters, smoking reduction rates ( ≥ 50% decrease in the number of cigarettes
smoked/day) from baseline for week-12 were 26%, 20% and 21% for groups A, B and C
respectively, while for week-52 smoking reduction rates were 10%, 9% and 12% for
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groups A, B and C respectively. Similary, smoking abstinence rates with an intention to
treat analysis for week-12 were 11%, 17% and 4% for groups A, B and C respectively,
while for week-52 abstinence rates were 13%, 9% and 4% for groups A, B and C
respectively.
Authors also examined outcomes releated to adverse events and product preferences.
A significant reduction in the frequency of reported symptoms from the baseline were
found at each clinic visit for all the three study groups. However, there were no
significant differences among the sutdy groups for the adverse events at each time
period. For the results related to the participants perception for e-cigs use over time,
participants were highly willing to recommend these devices to friends or relatives for
quitting smoking and found the overall product use to be satisfactory.
Study authors concluded that based on the study results, e-cigs holds a promise to help
smokers reduce the number of cigarettes smoked per day and can achieve abstinence
from tobacco for long time. As participants in this study were the one with no intention to
quit smoking, the overall smoking abstinence rate of 8.7% at 52-week along with the
significant decrease in the frequency of adverse events from baseline was noteworthy.
However, as the long term side effects associated with the e-cigs use were not a part of
this study, the study results questions uncertainty over its long-term use and absitnence
among regular smokers.
Bullen et al. 201343
Bullen et al. conducted pragmatic randomized-controlled superiority trial to investigate
the efficacy of e-cigarettes over nicotine patches for its use in smoking cessation. The
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study participants recruited were regular smokers from Auckland, New Zealand smoking
≥ 10 cigarettes per day for the past year, 18 years and older and with the intention to
quit smoking. Participants were randomized into three study groups into 4:4:1 ratio
using randomized block size nine design. Group A (n=289) received 16 mg nicotine ecigs, group B (n=295) received nicotine patches (21 mg patch, once daily) and group C
(n=73) received placebo e-cigarettes (no nicotine) from week-1 before until week-12
after quit day with low intensity behavioural support via voluntarily telephone
counselling. The e-cigarettes and cartridges utilized for this study were Elusion brand
products provided by PGM international. Primary outcome evaluated was biochemically
verified continuous smoking abstinence at 6 months (exhaled carbon monoxide (eCO)
level; concentration of < 10 ppm).
With an intent to treat analysis, out of the total 657 individuals who were randomized to
the above three treatment groups, verified continuous smoking abstinence at 6 months
after quit day was highest in group A (7.3%; 21 of 289), followed by group B (5.8%; 17
of 295) and group C (4.1%; 3 of 73). Risk difference for nicotine e-cigs vs patches was
1.51 (95% CI: -2.49 to 5.51) while for nicotine e-cigs vs placebo e-cigs was 3.16 (95%
CI: -2.29 to 8.61). Quit rates were higher initially and then it decreased significantly in
all study groups. In group A, 57% of study participants reduced their daily cigarettes
consumption by at least half at 6 months significantly while for group B it was 47%.
There were higher number of adverse events reproted for group A (137 events) over
group B (119 events) and group C (36 events). However, there were no significant
differences in the adverse events reported between study groups and there were no
evidence of association between adverse events and study intervention. Adherence to
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the study treatments were higher for group A and group C over group B for 1 st, 3rd and
6th month. Study participants were highly willing to recommend e-cigs device to friends
or family for quitting smoking as there was a sustained enthusiasm found to use these
devices even at 6th month.
Study authors concluded that e-cig devices with or without nicotine were modestly
effective in achieving smoking abstinence over nicotine patches and possess relatively
few adverse events associated with its use. However the study results cannot be
concluded with certainty as sample size was insufficient to conclude superiority of
nicotine e-cigs over pathces or to placebo e-cigs. Also, there were higher loss to followup and withdrawal rates for nicotine patches than those assigned to e-cigs group.
Further research is needed to establish more evidence for e-cigs long term benefits and
harms for its use in smoking cessation at invidual and population levels.
Adriaens et al. 201461
In this randomized controlled clinical trial, authors analyzed the effectiveness of second
generation e-cigs to evaluate acute cravings, smoking reduction and smoking
abstinence among regular smokers over the period of eight months. Study participants
who were unmotivated to quit were randomized into three groups; two experimental
groups both receiving e-cigs and one control group who received nothing and were
allowed to smoke continuously during the first 8 weeks of the study. Participants were
recruited from the area around Leuven, Belgium between December 2012 and February
2013. Participants were current smokers, smoking ≥ 10 factory made cigarettes for at
least 3 past years, not motivated to quit but willing to try out less unhealthy alternative.
Two types of e-cigs from second generation were evaluated (“Joyetech eGo-C” and the
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“Kanger T2-CC”). 30 ml bottles of flavored tobacco with 18 mg/ml of nicotine were used
as a volume and dose strength respectively. After attending the lab sessions,
participants were followed up at 3- and 6-months to assess changes in smoking
behavior and evaluate smoking cessation outcomes. Exhaled carbon monoxide (eCO)
and saliva cotinine levels were also measured.
Results indicates that at two months, among e-cig users group, 34% of them stopped
smoking tobacco cigarettes, whereas none of them were able to stop smoking
cigarettes in the control group (p < 0.01). At 5 th month, total quit rate among e-cig users
were 37% whereas the quitting rate among control group three months after initiating ecig use was 38%. Smoking abstinence rate at 8 month among e-cig users and control
group were 19% and 25% respectively. Overall there was 60% reduction in the amount
of cigarettes smoked/day at the end of study period when compared to start of the
study. 50% self-reported sustained abstinence at 8 th month among e-cig users were
observed in almost half of the participants (44%).
Authors concluded that among e-cig naïve tobacco smokers, second-generation e-cig
devices were highly effective in reducing the quantity of cigarettes smoked per day and
were helpful in reducing craving and withdrawal associated with tobacco smoke.
Prospective cohort studies
Polosa et al. 2011 (with intervention)62
Polosa et al. conducted a prospective 6-month pilot proof-of-concept study to evaluate
the efficacy of electronic cigarettes in smoking reduction and smoking abstinence and to
monitor possible modifications in smoking habits among regular smokers not willing to
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quit smoking. Study participants were healthy smokers, smoking ≥ 15 factory-made
cigarettes/day for at least past 10 years, between 18 and 60 years of age group,
unwilling to quit smoking and residing in Catania, Italy. Eligible participants were invited
to use popular e-cig brand ‘Categoria’ and were followed prospectively for 6 months (at
baseline, week-4, week-8, week-12 and week-24). Primary efficacy measure was
sustained 50% reduction in number of cigarettes smoked/day for 30 days period prior to
week-24 study visit from baseline (reducers). Secondary efficacy measure was
sustained 80% reduction in number of cigarettes smoked/day for 30 days period prior to
week-24 study visit from baseline (heavy reducers). Both these outcomes were selfreported and were also confirmed during the study visit by measuring eCO level
(concentration of ≤ 10 ppm) in participants breaths at the time of the interview.
Additional secondary efficacy measure was sustained self-reported and eCO confirmed
(concentration of ≤ 10 ppm) smoking abstinence at week-24 for 30 days period prior to
week-24 study visit.
A total of 40 participants were included and 67% (n = 27) of them completed this study.
Sustained 50% reduction in the number of cigarettes smoked/day at week-24 was
observed in 32.5% of the participants (13/40) with the median of 25 cigarettes
smoked/day at baseline to 6 cigarettes smoked/day at week-24 (p < 0.001). Sustained
80% reduction in the number of cigarettes smoked/day at week-24 was observed in
12.5% of the participants (5/40) with the median of 30 cigarettes smoked/day at
baseline to 3 cigarettes smoked/day at week-24 (p = 0.043). At week-24, sustained
smoking abstinence was observed in 22.5% (9/40) participants where 2/3 of those 9
were still using e-cigs at the end of the study. Overall at week-24, 55% (22/40)
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participants achieved both sustained 50% reduction and smoking abstinence with 88%
reduction in the number of cigarettes smoked/day. Adverse events that were frequently
reported were mouth (20.6%) and throat irritation (32.4%), and dry cough (32.4%),
however these adverse events reduced substantially at the end of study period. Number
of cartridges used/day were not more than three throught the study period. Product
opinion and acceptance was found to be good among study participants.
Authors concluded that e-cigs use, although currently not regulated as a pharmaceutical
products, can help smokers substantially in reducing the amount of cigarettes
smoked/day or can help in achieving smoking abstinence. Specifically with the currently
available pharmacotherpaies that are approved for smoking cessation, adding this new
device as an alternate to the available smoking cessation options can help bring more
smokers into treatment and can increase the numbers of smokers who are motivated to
quit tobacco. Susbstituting e-cigs over tobacco can surely help in saving lives. This is
the first e-cigs study that evaluated product efficacy and confirmed that these devices
can help in reducing the amount of tobacco consumed per day among smokers who are
unwilling to quit. However, the study findings pose some challenges as well. Due to the
lack of control group in this study and with high loss to follow up (32.5%), observed
positive effects can be simply due to chance and not the true effects. Also, due to its
unusual study design, study results cannot be compared with any other smoking
cessation products.
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Caponnetto et al. 2013 (with intervention)63
Capponetto et al. conducted a prospective 12-month pilot study to evaluate the efficacy
of electronic cigarettes in smoking reduction and smoking abstinence among regular
smokers with schizophrenia. Study participants were chronic schizophrenic patients
(confirmed using ICD-10 codes and DSM-IV-TR criteria for schizophrenia), regular
smokers smoking ≥ 10 cigarettes/day, not intending to quit and were recruited from
Catania, Italy. Eligible participants were invited to use popular e-cig brand ‘Categoria’
and were followed at baseline, week-4, week-8, week-12, week-24 and week-52.
Primary efficacy measure was sustained 50% reduction in number of cigarettes
smoked/day for 30 days period prior to week-52 study visit from baseline. Secondary
efficacy measure was self-reported smoking abstinence for 30 days period prior to
week-52 study visit and was objectively confirmed measuring eCO level (concentration
of ≤ 10 ppm) in breaths of study participants during their interview. Additionally, positive
and negative symptoms of schizophrenia were measured during each clinic visit. The
Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of
Positive Symptoms (SAPS) were used to assess the positive and negative symptoms of
schizophrenia.
A total of 14 participants were included and completed this study. Sustained 50%
reduction in number of cigarettes smoked/day at week-52 was observed in half of the
participants (7/14) with the median of 30 cigarettes smoked/day at baseline to 15
cigarettes smoked/day at week-52 (p = 0.018). At week-52, sustained smoking
abstinence was observed in 14.3% (2/14) participants. Overall at week-52, 64.3% (9/14)
participants achieved both sustained 50% reduction and smoking abstinence. Adverse
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events reported were nausea (14.4%), throat irritation (14.4%), headache (14.4%) and
dry cough (28.6%). The number of cartridges used/ day were not more than two
throught the study period. Patients using e-cigs did not have any increase in both
positive and negative symptoms of schizophrenia after smoking reduction or cessation.
Authors concluded that e-cigs use, although currently not regulated as a pharmaceutical
products, can help patients substantially in reducing the amount of cigarettes consumed
per day or can help in achieving smoking abstinence and reduce the overall burden of
smoking-related morbidity and mortality in schizophrenic patients who smokes
regularly. According to study participants, these devices had very few side effects and
had no apparent increase in the withdrawal symptoms. However, these study findings
cannot be easily translated and cannot be made generalizable due to very small sample
size these study had. Study results are questionable for interpretation as positive effects
due to e-cigs could have been simply due to chance and not a true product effect. Also,
these results cannot be compared with any other smoking cessation products because
of the type of patient population that was being analysed.
Ely J 2013 (with intervention)64
The studys main objective was to offer a new smoking cessation alternative; ecigarettes along with other available options for quitting smoking in order to increase
overall smoking cessation rates among current smokers residing in Moffat county and
multiple surrounding areas of northwestern colorado. The secondary objective was to
offer e-cigarettes as an alternative to tobacco smoke among those individuals who were
not motivated to quit but were willing to switch to this new alternative which was
hypothesized to be safe and cheaper over other alternatives. This program was
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conducted at the Kinder Family Clinic for 6 months on a trial basis. Study intervention
goal was to implement the structured, systematic smoking cessation program based on
the ‘5 As’ and the transtheoretical model to treat tobacco use and dependence.
Participants were informed of the variety of options at the beginning of the study and
were provided with printed information on ‘smoketips’ and ‘blu cig’ e-cig brands, costs,
nicotine dosage options and availability. Participants were provided a questionnaire and
were followed up using telephone at 2-weeks, 1 month, 3 months and 6 months after
the use of intervention.
A total of 44 participants were recruited in this study where all of them used e-cigs, 16
used bupropion, and 2 used Varenicline. Number of participants who quit smoking were
32% (14/44) and 16% (7/44) of them switched to e-cigarettes. Of those who completely
quit smoking (n = 14), 10 used solely e-cigs, 2 of them used bupropion and the rest
used Varenicline. Of the 7 who switched to e-cigarettes, 3 of them used solely e-cigs
and the rest used both, e-cigs and bupropion. A total of 23 remaing participants were
unable to quit smoking, 30% (13/23) were able to reduce their daily smoking to half of
their initial smoked level along with intiating the use of e-cigarettes. 6-month smokming
cessatiion rate was 44% (21/44). Smoking cessation rate or switching rates to ecigarettes were both double in comparison to the national and state averages of 2124%, indicating intervention success and significant harm reduction for patients and
families. Overall, smoking abstinence was not clearly defined nor was verified
biochemically and hence possess high risk for other biases.
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Polosa et al. 2014 (with intervention)65
Polosa et al conducted a 24-month prospective observational study to evaluate the
long-term effectiveness and tolerability of e-cigarettes in the real world settings. Study
participants included were healthy current smokers, smoking ≥ 15 factory-made
cigarettes per day for at least past 10 years, were not motivated to quit smoking and
were recruited from the local hospital staff in Catania, Italy. Eligible participants were
invited to use popular e-cig brand ‘Categoria’ for a period of 6 months and were
followed up prospectively for 24 months (at baseline, week-4, week-8, week-12, week24, 18-months and 12-months). Efficacy measures evaluated were (1) 50% reduction in
number of cigarettes smoked/day from baseline (reducers) at each study visit and was
objectively confirmed by measuring eCO level (concentration of ≤ 10 ppm) in breaths of
study participants during their interview. (2) 80% reduction in number of cigarettes
smoked/day from baseline (heavy reducers) at each study visit and was objectively
confirmed by measuring eCO level (concentration of ≤ 10 ppm) in breaths of study
participants during their interview. (3) Sustained self-reported and eCO confirmed
(concentration of ≤ 10 ppm) smoking abstinence at each study visit.
Out of 40 subjects, almost 50% (n =23) of them completed this study. 50% sustained
reduction in the number of cigarettes smoked/day at 6-, 18- and 24-months were
observed in 10/40, 11/40 and 11/40 participants respectively with significant reduction in
the median number of cigarettes smoked/day at 24-months (24 cigarettes smoked/day
at baseline to 4 cigarettes smoked/day at 24 months). 80% sustained reduction in the
number of cigarettes smoked/day at 6-, 18- and 24-months were observed in 4/40, 3/40
and 6/40 participants respectively with reduction in the median number of cigarettes
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smoked/day at 24-months (27.5 cigarettes smoked/day at baseline to 4 cigarettes
smoked/day at 24-months). Smoking abstinence at 24-months was observed in 12.5%
(5/40) participants while 40% (16/40) participants achieved both, 50% reduction and
smoking abstinence). At the end of the study, 5 participants stopped using e-cigs, 3
started using tobacco again and 4 upgraded to more advanced e-cig prodcuts. Adverse
events reported were mouth and throat irritation, and dry cough. There were hardly any
withdrawal symptoms that were reported for this study.
Authors concluded that e-cigs can extensively help in reducing the amount of cigarettes
smoked/day and can help in achieving smoking abstinence among smokers who are
unwilling to quit smoking. This is the first study to examine the efficacy of e-cigs in
smoking reduction and smoking abstinence for a long term period and in the naturalistic
settings. Study results strongly supported e-cigs use and are more effective than
approved pharmacotherapies for smoking cessation in more realistic settings. However,
as there was a lack of control group in this study design along with higher loss to follow
up, it presents challenges for applicability of study results to other settings.
Polosa et al. 2014 (with intervention)66
Polosa et al conducted a proof-of-concept prospective study to evaluate possible
modifications in the daily cigarettes smoked among current smokers who switched to
second-generation e-cigarettes with the focus on smoking reduction and abstinence.
Study participants were healthy smokers, between 18 and 60 years old, smoking ≥15
factory made cigarettes per day for at least 10 years, not motivated to quit and residing
in Catania, Italy. Qualified participants were invited to use a second-generation ecigarettes device: EGO/CE4 model filled with tobacco aroma e-liquid containing 9mg/ml
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of nicotine. Participants were followed prospectively for 6-months at baseline, week-4,
week-8, week-12, and week-24. Efficacy measures evaluated were (1) Self-reported
sustained 50% reduction in number of cigarettes smoked/day compared to baseline for
30 day period prior to week-24 (reducers). (2) Self-reported sustained 80% reduction in
number of cigarettes smoked/day (heavy reducers) and sustained abstinence (quitters)
from baseline at week-24. The eCO levels were also measured to confirm smoking
reduction and abstinence (concentration of ≤ 10 ppm) during their interview. Smokers
who werent able to qualify for either reducers, heavy reducers or quitters were
categorized as failures.
A total of 50 smokers participated in this study, with 38 of them being able to complete
this study. 50% and 80% sustained reduction in the number of cigarettes smoked per
day at week-24 was observed in 30% (15/50) and 14% (7/50) participants with
significant reduction in the median number of cigarettes from 25 cigarettes smoked/day
at baseline to 6 cigarettes smoked/day and 3 cigarettes smoked/day at week-24
respectively. Smoking abstinence at week-24 was observed in 36% (18/50) participants,
with 83.3% (15/18) of them still using the e-cig device. Collective 50% reduction and
smoking abstinence was observed in 66% (33/50) participants. Adverse events reported
were throat and mouth irritation (35.6%), dry throat and mouth (28.9%), headache
(26.7%) and dry cough (22.2%). However, frequency of these reported events
decreased substantially near the study completion. Overall patient’s acceptance and
preferences in handling these second-generation devices were good.
Smoking abstinence and reduction rates obtained in this study were not only higher in
comparison to the reduction and abstinence rates for standard smoking cessation
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options but were also higher in comparison to the smoking cessation studies using first
generation devices. This may be due to high level of product satisfaction and reliability
associated with the use of second generation devices. Study authors concluded that the
use of second generation e-cigarettes in smoking cessation can help smokers in
reducing the quantity of tobacco smoked per day along with increasing the likelihood of
remaining abstinent for a long period of time. However, results cannot be made
generalizable due to presence of study challenges such as lack of control group along
with 32.5% of loss-to-follow up. Further study is needed that can compare first and
second generation devices for its efficacy related to smoking reduction and abstinence.
Pacifici et al. 2015 (with intervention)67
Pacifici et al conducted 8-month pilot study among adult smokers to evaluate whether
medically assisted e-cigarette uers were able to use nicotine successfully or not. In this
pre-post uncontrolled pilot study, participants were adult smokers, not motivated to quit
smoking, have never tried quitting tobacco use, and/or have never tried any smoking
cessation treatments. Participants were recruited by word of mouth and it was
conducted at the anti-smoking Centre at San Giovanni Bosco Hospital (Torino, Italy).
Since 2000, this centre supplies customized smoking cessation treatments to an
average of 300 smokers/year. Participants were given a couple of commercially
available e-cigs AVATAR device, chargers and nicotine liquid (that matches individuals
daily nicotine intake). Further, they were given face-to-face medical training for how to
correctly use e-cig devices to absorb nicotine vapor. Participants were followed up at
first, fourth and eigth month for analysis of eCO level, blood cotinine and
hydroxycotinine levels along with the information on number of cigarettes smoked/day.
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Total of 34 participants were recruited for this study and were aged 18-63 years old. At
the end of first month, participants were grouped as only e-cig users (73%), dual users
(17.6%) and only cigarette users (8.8%). Over time, significant reductions in the eCO
level were found for both e-cig users only and dual users group. Overall smoking
abstience at the end of 8-month was about 53%. Also, number of cigarettes
smoked/day decreased significantly at 8-month for all three groups compared to the
start of the study. However, no significant differences were found for the cotinine and
hydroxy-cotinine levels for any any of the groups.
Authors concluded that providing medical training to smokers on how to use e-cigs
device can help in successful nicotine intake, can reduce the overall craving for
cigarettes and can avoid side-effects associated with nicotine overdosage. However
due to lack of control group and less sample size, study results cannot be made
generalizable. Further results from clinical trial study evaluating medically assisted use
of e-cigs with more number of participants are needed.
Polosa et al. 2015 (with intervention)68
In this study, authors evaluated the changes in the quanity of cigarettes smoked/day
among smokers who made their first e-cigs purchase at vape shops. This was a
prospective pilot study conducted for 12-months with study participants being adult (≥
18 years) and making their first e-cig purchase at the participating local vape shops in
the city of Cantania (Sicily). Participants were motivated to use e-cig products with the
purpose of achieving reduction in the amount of cigarettes smoked/day. Participants
were asked specific set of questions by the professional retail staff and were followed
prospectively at 6-months and 12-months. Participants were instructed on how to
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charge, fill, activate and use e-cig products. Study outcomes evaluated were (1) Selfreported sustained 50% reduction in number of cigarettes smoked/day compared to
baseline for 30 day period prior to a follow-up visit (reducers). (2) Self-reported
sustained 80% reduction in number of cigarettes smoked/day (heavy reducers) and
sustained abstinence (quitters) compared to baseline for 30 day period prior to a followup visit. Smokers who werent able to qualify for either reducers, heavy reducers or
quitters and those who were lost to follow-up were categorized as failures. Changes in
product purchases were also evaluated.
Out of 71 participants who made their first e-cig purchase at local vape shops, 69% of
them attended their final follow-up visit. With an intent to treat analysis, at the end of
study (12-month), 25.4% were reducers, 40.8% were quitters and 33.8% were failures.
Analyzing the whole cohort (n=71), the quantity of cigarettes smoked/day decreased
from 24.9 cigarettes smoked/day (at baseline) to 4 cigarettes smoked/day and 2.6
cigarettes smoked/day at 6- and 12-months respectively. Overall, aggregated smoking
abstinence and smoking reduction at 12 months was observed in 66.2% (47/71)
participants, with the mean number of cigarettes smoked/day being 24.7/day at baseline
decreasing to 2.2 cigarettes smoked/day at the end of the study (89.1% reduction).
Smoking abstinence rates at 6- and 12-months were 42% (30/71) and 41% (29/71)
respectively. The combined usage (smoking and e-cig use) at 12 months was 66.2%
indicating higher product satisfaction.
Authors concluded that smokers making their first e-cig purchase from local vape shops
and if provided professional advice and support can help in reducing the quanity of
cigarettes smoked/day along with the increase in rates of achieving smoking
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abstinance. However, limitations to this study were that both smoking reduction and
abstinence were self-reported and were not biochemically verified. Additionally, due to
less sample size, self-selection of participants and absence of controlled group, results
cannot be generalized and cant be interpreted for its true effect.
Etter et al. 2014 (without intervention)44
Etter et al. conducted a longitudinal internet survey from 2011 to 2013 to evaluate
behaviour change among e-cig users over a period of 12 months. Survey participants
were registered online through smoking cessation website Stop-Tabac.ch
(http://www.stop-tabac.ch/fr/) and were provided a questionnaire in english and french
at baseline, 1-month and a year after to collect information on e-cig use, current
smoking status, use of tobacco in previous 7 days, number of cigarettes consumed/day,
puffs/day (1-year) and quitting date in former smokers. Participants with age over 18
were only included in this study. Stop-Tabac.ch website ranks among the top five global
sites for smoking cessation. It offers an online free help to smokers who wants to quit
smoking, wants to prevent relapse and needed motivation to quit smoking. It provides
information about smoking, its consequences and treatments and facilitates an
opportunity to exchange dialogues between smokers and ex-smokers.
Out of 1329 participants who answered survey at the baseline, 773 (58%) of them
provided their email address. Out of those who provided their email address, 62% and
47% of them participated in the survey at 1-month and 1-year respectively.
Respondents were from the US (34%), France (24%), UK (8%), Switzerland (6%) and
other countries (28%). Majority of the participants were former smokers (72%), 76% of
them were using e-cigs daily much like nicotine medications to assist quitting and were
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abstinent from smoking for a median of 10 weeks. Among former smokers who were
vaping daily at the baseline, 6% relapsed to smoking at both 1-month and 1-year.
Among dual users (daily smokers and e-cig users), 22% and 46% stopped smoking
after 1-month and 1-year respectively. Cigarette consumption among dual users
decreased significantly from 11.3 cigarettes smoked/day at baseline to 6.0 cigarettes
smoked/day at 1-month. However, it didn’t change significantly from baseline till 1-year
of follow-up.
As the study participants were from different countries with the survey response coming
from the users who were in the real world settings, this study provided most detailed
information on the natural behavior change for e-cigs use over 12 month period.
Authors concluded that e-cigs act as an alternative to smoking, can help current
smokers in quitting smoking and can help former smokers in avoiding relapse. The
results agreed to the formerly conducted similar longitudinal and clinical trials for
vapers. However, study results possess major limitations such as self-reported and selfselection bias. Further research is needed that can evaluate health consequences of ecigarettes use in long term.
Grana et al. 2014 (without intervention)69
Grana et al conducted a longitudinal online survey among current smokers to evaluate
whether e-cigarettes were helpful in quitting smoking or in reducing the quantity of
cigarettes consumed per day. Participants recruited were from the Knowledge
Networks; probability based online survey. Current smokers who completed baseline
survey (November 2011) and follow-up (November 2012) online surveys were the one
included in this study. E-cig use, number of cigarettes consumed/day, time to first
50

cigarette, and intention to quit were measured at baseline and follow-up. Descriptive
and regression analysis were conducted on these study variables.
Out of the total 1549 participants who were on the 2011 and 2012 survey panel, 1189
were current smokers and 81.3% completed the follow-up survey. Greater amount of ecig users were among women, younger adults and those with less education. Baseline
e-cig use among current smokers was not associated with greater intention to quit
smoking (p = 0.09). In addition, the use of e-cig at baseline did not predict quitting
smoking 1-year later (OR: 0.76; 95% CI: 0.35, 1.46). However, study model that
included intent, dependence and consumption study variables found that intent (OR:
5.59; 95% CI: 2.41, 12.98) and consumption (OR: 0.97; 95% CI: 0.94, 0.99) significantly
predicted quit status. Among those who were smoking both at the baseline and followup, e-cig use was not associated with the change in cigarette consumption (p =0.25).
Authors concluded that e-cigarettes may not help smokers in quitting smoking or
reducing the amount of cigarettes smoked and hence proposed that regulations should
prohibit any advertisement of e-cigs that claims it to be effective in smoking cessation
unless scientific evidences supporting its use in smoking cessation becomes available.
The study results were in agreement to the other longitudinal population-level study.
These study pose several study limitations such as lack of detailed information on
frequency, duration, use patterns and motivation for e-cig use, self-reported bias and
was limited in statistical power to conclude for the significant relationship between e-cig
use and quitting.
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Borderud SP et al. 2014 (without intervention)70
In this study, authors analyzed clinical characteristics and cessation outcomes among
cancer patients who were referred to the Tobacco Treatment Program (TTP) at
Memorial Sloan-Kettering Cancer Center, New York from January 2012 till December
2013. Participants in this study were current smokers, diagnosed with cancer and
referred to the TTP. E-cig users were those who responded yes to using these devices
within 30 days prior to enrollment. Patient information was collected at baseline and
were followed up at 6th and 12th months through telephone to collect information on
smoking cessation.
Out of total 4054 patients who were referred to this program, 1074 of them were
recruited. During baseline, around 25% of the patients (n=285) were using e-cigs; 92%
of them reported smoking tobacco as well. The number of e-cig users increased 3 times
from 2012 to 2013 (10.6% vs. 38.5%). There were no significant differences for
demographic characteristics between e-cig users and nonusers. Among those using ecigs, proportion of use were higher among those with thoracic or head and neck
surgery. Also, e-cig users were more nicotine dependent and had more prior quit
attempts in comparison to nonusers. With an intent to treat analysis, e-cig users were
highly likely to be smoking tobacco at the follow-up in comparison to nonusers (OR: 2.0;
95% CI: 1.2 to 3.3)
Authors concluded that in past two years, awareness and use of e-cigs has not just
increased in the general population, but it has also shown rise in disease population
such as those having cancer. However, there is still an uncertainty regarding the use of
this device officially for smoking cessation in cancer patients. Further studies are
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needed that can evaluate the effectiveness of this devices as a cessation treatment in
patients with cancer.
Prochaska et al. 2014 (without intervention)71
In this secondary analysis from a three group randomized clinical trial data, authors
evaluated whether e-cig use was associated with any changes in smoking behavior
among patients with mental illness. Participants recruited for this study were adult
smokers smoking at least five cigarettes daily, not willing to quit tobacco and were
recruited during their acute psychiatric hospitalization. Recruitment was done in San
Francisco Bay area during 2009 and 2013, with the study intervention being tailored and
computer assisted for readiness to quit, a stage-tailored manual, brief stage-tailored onunit counseling session with study staff, and participants were provided combination
nicotine replacement therapies available following hospitalization. NRT was offered for 3
months in the brief treatment arm and for 6-months in the extended treatment arm. The
latter group also received 10 sessions of cognitive behavioral cessation counseling.
Participants were followed up at 3, 6, 12 and 18 months.
73% (n = 956) of adult smokers were enrolled at the baseline. Average number of
cigarettes smoked/day at baseline was 17 (SD =10) and 24% of them intended to quit
smoking in the next month. E-cig use increased from 0% at the year of enrollment to
25% in 2013. The likelihood of using e-cig increased with each additional year of
recruitment, for those between 18 and 26 years, for those in the preparation vs precontemplation stage of change. At 18 month, e-cig use was not associated with either
change in smoking status or reduction in the quantity of cigarettes smoked per day.
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Authors concluded that among current smokers with mental illness, e-cig use has
increased over time. However, there was no correlation found between those using ecigs and smoking status or quantity of cigarettes consumed per day and challenges
interpretability of study results due to the presence of self-selection and reporting bias.
Choi et al. 2014 (without intervention)72
Authors in this study evaluated a longitudinal data to analyze the relationship between
the beliefs and perceptions to its subsequent experimentation with e-cigs. Minnesota
Adolescent Community Cohort (MACC) data was utilized. Participants were young
adults (N = 1379) from Minnesota who never used e-cigs at baseline (Oct 2010 until
March 2011) and were able to follow up at 1-year (Oct 2-11 until Mar 2012). At baseline,
participants were asked about their beliefs for e-cigs with respect to its harmfulness,
addictiveness and as a potential for quitting smoking. At the end of study, information
regarding their ever usage of e-cigs were collected. Association between beliefs and
subsequent experimentation with e-cigs were evaluated with the help of logistic
regression models.
Results found that during the end of study, 7.4% (n = 102) participants reported using ecigs ever, 21.6% of whom were baseline current smokers. Participants with the positive
beliefs that e-cigs can help people in quitting smoking and are less harmful than
conventional cigarettes were the ones to be more likely to be experimenting e-cigs at
follow-up (p <0.05). Authors also found that 11% of smokers who had ever used e-cigs
at baseline had quit smoking at 1-year follow-up compared with 17% of smokers who
had never used e-cigs.
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Results from this study cannot be made generalizable due to the presence of
predominantly white sample and participants coming from one particular region. Authors
concluded that prior beliefs about e-cigs are highly associated with the subsequent
experimentation to these products. However, due to existing uncertainty with e-cigs
long-term harmfulness and addictiveness, providing young adults with these may
discourage them from trying these products.
Brown et al. 2014 (without intervention)45
In this large cross sectional survey, authors examined the effectiveness of e-cigarettes
over standard therapies available for smoking cessation in the real world setting.
Participants were adult population (n = 5863) representative of the English population
residing in England, recruited between July 2009 until February 2014, who smoked or
used any tobacco products at the time of recruitment, made at least one quit attempt
with either e-cigs only (n = 464), or bought OTC NRT only (n = 1922) or no aid (n =
3477) in the past one year before enrollment. Primary outcome was adjusted selfreported smoking abstinence until the time of survey.
Results indicated that those who used e-cigs for quitting were more likely to remain
abstinent from smoking (OR: 2.23; 95% CI: 1.7 to 2.93) in comparison to those who
used NRT purchased OTC. After adjusting for key potential confounders, the odds of
not smoking were still higher among e-cig users (OR: 1.63; 95% CI: 1.17 to 2.27) in
comparison to those using NRT or using no aid.
Authors concluded that those using e-cigs as a smoking cessation tool were more likely
to have continued smoking abstinence. However due to the nature of study design, it
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questions the observed true effectiveness and temporality. Additionally, smoking
abstinence was not biochemically verified and there was a heavy reliance on recall
data.
Brose LS et al. 2015 (without intervention)73
In this study, authors evaluated the association between e-cig use and smoking
cessation attempts, cessation and substantial reduction among smokers while
considering for frequency of use and including important confounders. A web-based
longitudinal survey was conducted in Great Britain between 2012 and 2013. Study
participants were invited online through a panel managed by Ispos MORI. Ispos MORI
is one of the biggest market research organization in the UK. Participants were emailed
questionnaires at baseline and at 1-year. Outcomes evaluated were cessation attempts,
cesation and ≥ 50% self-reported substantial reduction in number of cigarettes
smoked/day. Further, adjusted logistic regression models were built to analyze the
association of cessation attempt in last year and smoking status on baseline e-cig use.
Additionally, the association between substantial reduction and follow-up e-cig use were
also evaluated while adjusting for all the required variables.
Total 5000 respondents completed this survey, 4064 of them were current smokers with
age over 18. Loss to follow-up was 43% (1759/4064) indicating that 46% of them
attempted to quit smoking in 1-year. Of those using e-cigs at baseline, majority of them
were first generation e-cig users (‘Cigalike’). Daily e-cig use at baseline was associated
with increased odds of cessation attempts but not with cessation in comparison to nonuse. (OR: 2.11; 95% CI: 1.24-3.58). Daily e-cig use at follow-up was associated with
increased odds of substantial reduction (OR: 2.49; 95% CI: 1.14-5.45). However, non56

daily use was found to be neither associated with cessation attempts nor cessation.
Smoking abstinent rate at 12-months among the participants was found to be very low
(8%).
Authors concluded that regular use of e-cigs among smokers can help in increasing the
rates of quit attempts and reducing smoking. However, they might not be that helpful in
smoking cessation. However, nature of this study design warrats the applicability of
study results to make it more generalizable. This study poses challenges such as
selection bias, attrition bias and reporting bias.
Al-Delaimy et al. 2015 (without intervention)74
In this prospective cohort study, authors evaluated whether ever use of e-cigs among
smokers affected smoking abstinence and smoking habits among general population in
comparison to those who never used e-cigs. California Smokers Cohort (CSC) data was
analyzed at two time points; at baseline and at 1-year among current and former
smokers residing in California. Baseline survey consisted of telephone interview of 4350
residents from California who were between 18 and 59 years old and had smoked at
least 100 cigarettes during their lifetime. At baseline, 83.6% were daily smokers and
236 participants reported using E-cigs at that time point. During the follow-up at 1-year,
1745 participants responded over telephone of whom 1000 were smokers at baseline.
Analysis involved only smokers who reported using e-cig at both baseline and follow-up.
Self-reported abstinence at 1-year, quit attempts and smoking reduction were assessed
at 1-year. Logistic regression model was developed to assess the association of history
of use of e-cigs at baseline to predict quitting behavior at 1-year follow-up after adjusting

57

for confounders at baseline. Analysis involved only smokers who reported using e-cig at
both baseline and follow-up.
Authors found that females, Hispanic whites and daily smokers were the one who were
significantly more likely to report using e-cigs ever both at baseline and follow-up. In
contrast to other studies, these study found that in comparison to smokers who never
used e-cigs, smokers who used e-cigs ever were significantly less likely to reduce their
daily amount of cigarettes smoked (OR: 0.51; 95% CI: 0.30 to 0.87), and were also less
likely to quit smoking for 30 days or more at 1-year (OR: 0.41; 95% CI: 0.18 to 0.93).
Smoking abstinence at 12-months was 5% (12/236) among ever e-cig users while
among never e-cig users, it was 10.5%. However, those who used e-cigs ever were
more likely to have a quit attempt (OR: 1.15; 95% CI: 0.67 to 1.97).
Authors concluded that those who had ever used e-cigs pose a higher risk of not being
able to quit smoking; a study finding which contrasts majority of study findings from
randomized clinical trials and experimental studies. However, this study possesses
major challenges such as risk of recall bias, self-selection bias and attrition bias. Also,
intervention was not clearly mentioned and authors didn’t collect information on the type
of e-cigs used as this could affect study results. Additionally, motivation status of
participants were also not clear.
Manzoli 2015 et al. (without intervention)75
In this prospective cohort study, authors evaluated the safety and efficacy of ecigarettes as a tool for smoking cessation by comparing only e-cig users, only tobacco
smokers and smokers of both. This study was initiated in 2013 in a community settings
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in Abruzzo, Italy and is expected to follow-up until 5 years to evaluate long-term efficacy
of e-cigs, with the final study results being expected in 2019. However, authors have
published main results from the 1-year follow-up. Participants were recruited through
direct contact with physicians and e-cig shops by posting online advertisement and
social networks. Participants between 30 and 75 years of age group were included and
were grouped either as e-smokers (had smoked any brands of e-cigs and inhaling ≥50
puffs weekly for the past 6 months), or tobacco smokers (smoked ≥1 tobacco cigarette
per day for the past 6 months) or dual smokers (smoked both e-cigs and tobacco within
the same week for past 6-months). Participants were surveyed face-to-face at baseline
and through telephone at 12-months using structured survey questionnaire. Outcomes
evaluated were self-reported sustained (30 days) smoking abstinence at 12-months with
CO validation for subsamples, proportion of quitters, quantity of tobacco cigarettes
smoked, adverse events and self-reported health. Linear and logistic regression models
were developed with region as a cluster unit.
During 12-momths, follow-up data were available for 491 tobacco smokers, 236 e-cig
smokers and 232 dual smokers, with response rate being 70.8%. All e-cig users were
former tobacco smokers since more than 20 years on average. At follow-up, 61.9%,
20.6% and 22.0% were abstinent from tobacco smoking among e-cig users, tobacco
smokers and dual smokers respectively. Multivariate regression model results indicated
that odds of continued tobacco smoking abstinence were higher among e-cig users
(OR: 5.19; 95% CI: 3.35 to 8.02) in comparison to the tobacco users only. However,
odds of remaining abstinent from smoking tobacco were not significant among dual
users in comparison to tobacco users only, nor did it increased likelihood of reducing
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tobacco consumption. Self-rated health among e-cig users were minimal but
significantly higher in comparison to other groups. Adverse events reported among
three groups were not significant.
This is the first study that compares e-cig users with tobacco users and aims to collect
long-term safety and efficacy data on e-cigarettes. With the study getting over in 2019, it
will be interesting to see the real world effectiveness of these devices when used for
long time and percentages of those being relapsed to smoking. Based on preliminary
analysis of one-year data, authors concluded that there were no major safety concerns
reported among e-cig users. Among dual users and tobacco smokers, there were no
significant reduction in the quantity of cigarettes consumed and smoking abstinence.
However, e-cig users were able to remain abstinent from smoking for long period along
with no major safety issues being reported, holding them to be promising as an
important tool to be used in smoking cessation. This study is further planned to have a
follow-up at 24-months, 36-months and 60-months.
Summary of the literature
Of all the included studies that have attempted to measure the effect of e-cigarettes in
smoking cessation, most of them were online surveys or telephone based surveys,
while the rest were conducted either at clinics, or at particular region. The majority of
them included participants that were healthy adults (with age 18 and above), currently
smoking tobacco and were not motivated to quit tobacco, while in the studies by
Caponetto et al. and Borderud et al. it was specifically targeted among patients having
schizophrenia and cancer respectively. Further, in many studies there was no specific
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intervention that was being studied or applied, as the habits of using e-cigs were
evaluated to analyze the smoking cessation outcomes.
Currently e-cig devices are available in various brands and flavors.49 They are mostly
categorized into four-generation devices with respect to different size and shape
available. Also, they are available online for purchase with different levels of nicotine
concentrations in cartridges (refilled and not-refilled). As a result, there is a considerable
variability in nicotine vaporization between different types of e-cigarettes leading to
different results for smoking cessation.32 A major challenge that remains with all the
above included studies is that majority of them have considered first generation e-cigs
device for its effectiveness in smoking cessation (using ‘cigalikes’). However, a study by
Adriaens et al. conducted a randomized controlled trial to actually compare two second
generation e-cig devices for its product effectiveness in cessation. Effectiveness of
these devices in cessation using either third or fourth generation still remains
questionable. Further, only 2 studies (Brown et al. and Bullen et al.) did compared the
effectiveness of e-cigs with NRT’s. There were no head-to-head trial comparison
studies available that compared e-cigs with other standard pharmacotherapies such as
Varenicline or Bupropion. Such comparison studies are needed in the future to evaluate
the product efficacy and to conclude for smoking abstinence. Smoking reduction
outcomes that were evaluated were reduction in number of cigarettes consumed per
day and smoking cessation. ≥ 50% reduction in number of cigarettes smoked per day
ranged from 25% to 57% at 6-months, 50% at 12-months, 28% at 24-months. ≥ 80%
reduction in number of cigarettes smoked per day ranged from 1% to 14% at 6-months
and was 15% at 24-months. Self-reported continuous smoking abstinence rate for all
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the above included studies ranged from 7.3% to 44% at 6-months, 5% to 53% at 12months and 13% at 24-months.
The majority of the studies found significant differences in the results related to smoking
cessation outcomes compared with NRT’s and no cessation options and concluded that
e-cigs can be used officially as a smoking cessation alternative and can help smokers
substantially in reducing the amount of cigarettes consumed per day, can help in
achieving smoking abstinence, and can reduce the overall burden of smoking-related
morbidity and mortality. However, few of them didn’t find any significant difference and
concluded them to be not helpful in quitting smoking. In fact they concluded that such
devices can serve as a gateway to start smoking tobacco. Overall, from all the studies
included, it is not possible to draw a reliable conclusion from these published study
results for the effectiveness of e-cigarettes in smoking cessation due to methodological
limitations such as self-selection bias, self-reported bias, poor sampling techniques or
recruitment methods, inadequate blinding, wide confidence intervals or lack of statistical
significance, and low internal validity. Also, scarcity of controlled studies regarding the
effectiveness of e-cigs in broader population presents another challenge with regards to
the generalizability of study results.
2.2: Gaps in the literature
Existing literature have evaluated efficacy and safety of e-cigs for smoking cessation.
However, majority of them have evaluated smoking abstinence mainly in healthy adults,
who were currently smoking and were not motivated to quit. None of them have
evaluated the effectiveness of these devices among COPD patient population, as
smoking cessation is the only evidence-based strategy that is identified to improve the
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prognosis of COPD. Smoking cessation in COPD individuals has been shown to
improve health status, decrease the respiratory symptoms of cough and sputum and
has diminished the rate of annual decline in pulmonary function.76 It has also shown to
reduce the risk of developing lung cancer, cardiovascular disease and other smokingrelated illness.21 Further, all studies have compared efficacy and safety of e-cigs either
with placebo or with NRT’s. None of them have compared e-cigs with other standard
available prescription pharmacotherapies such as Varenicline or Bupropion. Even
though these prescription pharmacotherapies and NRT’s have shown to encourage
cessation among current smokers with COPD, the relapse rate is very high when
compared to smokers in general population.77 Due to more frequent relapses and
ineffective smoking cessation among COPD patients, improved quit rates would be
highly desirable among these specific group of patients, demanding the need for more
efficient and novel approaches to quitting smoking. Considering much increased
awareness, popularity and use of e-cigs device for smoking cessation, it will be very
essential to conduct a study that can compare these pharmacotherapies with e-cigs
directly in order to evaluate the product efficacy for longer duration on the basis of
established evidences. Another gap identified in the literature is that it remains unknown
as to how introducing e-cigs as a smoking cessation therapy will impact the US
healthcare budget, especially among COPD patient population. Further, there remains a
need to estimate the prevalence and identify e-cig user characteristics among COPD
patient population as these estimates can give a detail picture about the actual uptake
and user characteristics of these devices among COPD patient population.
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2.3: Specific Aims
Aim 1: To estimate the prevalence and study sociodemographic predictors for ecig users among individuals with COPD in the United States (US)
A. To estimate the prevalence for current e-cig users and ever e-cig users among
individuals with COPD
B. To identify the sociodemographic predictors for current e-cig users among individuals
with COPD
C. To examine the association between current e-cig users and sociodemographic
predictors among individuals with COPD
Aim 2: To examine the predictors and estimate the total healthcare cost among
current smokers with COPD in the US
A. To examine the sociodemographic and clinical characteristics among current
smokers with COPD
B. To estimate the unadjusted total, direct and indirect healthcare cost among current
smokers with COPD
C. To estimate the adjusted total, direct and indirect healthcare cost among current
smokers with COPD
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Aim 3: To estimate the economic impact of adopting e-cigarettes as a smoking
cessation tool among current smokers with COPD in the US
A: To estimate the 1-year and accumulated 5-year total healthcare cost savings
associated with E-cigarettes (e-cigs) use in comparison to smoking cessation therapies
among current smokers with COPD in the US
B: To estimate the 1-year and accumulated 5-year total healthcare cost savings by
gender associated with e-cigs use in comparison to smoking cessation therapies among
current smokers with COPD in the US
C: To estimate the 1-year and accumulated 5-year total healthcare cost savings by
different age groups associated with e-cigs use in comparison to smoking cessation
therapies among current smokers with COPD in the US
2.4: Study significance:
E-cig devices are unregulated by the US FDA and their use have dramatically
increased. At the same time, many organizations are strongly advocating the use of
these devices in quitting smoking. Hence, analyzing and understanding the economic
impact of adopting e-cig devices amongst COPD diagnosed populations can help
answer policy questions related to their use in smoking cessation. The results from this
study can help policy makers, payers, consumers and clinicians make informed
decisions about its use as a therapeutic device.
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Chapter 3: Specific Aim 1
Aim 1: To estimate the prevalence and study sociodemographic predictors for ecig users among individuals with COPD in the United States (US)
A. To estimate the prevalence for current e-cig users and ever e-cig users among
individuals with COPD
B. To identify the sociodemographic predictors for current e-cig users among individuals
with COPD
C. To examine the association between current e-cig users and sociodemographic
predictors among individuals with COPD
3.1: Methods
Design: Retrospective, cross-sectional design
Data
The National Health Interview Survey (NHIS) data was utilized for this study. The NHIS
is an annual cross-sectional survey of the nationally representative, noninstitutionalized, US civilian population. The survey is conducted annually by the
National Center for Health Statistics of the CDC. It uses a complex, stratified,
multistage, probability design, where data collection comes from face-to-face interviews
of participants with age 18 and above. This data monitors the health of the US
population by collecting relevant information on the sociodemographic and economic
characteristics of the sample participants. Further information on the NHIS methodology
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is available online.78 This study was exempt from the Institutional Review Board (IRB)
as this data is publicly available.
Study population
The 2014 sample adult file was utilized to measure the study objective, as this was the
first time that the information regarding the usage for e-cigs were captured in the NHIS
survey questionnaire. The sample file consisted of 36,697 survey respondents with age
18 years or older with the response rate from the survey participants being 58.9%. For
this study, participants with age 18 and above, and having diagnosed with COPD were
included. Individuals with COPD were the ones who answered yes to the following
survey question:


Have you EVER been told by a doctor or other health professional that you had
chronic obstructive pulmonary disease, also called COPD?

Study variables
Key variable for this study was e-cigarettes use. Current e-cig users were defined as
those having responded using e-cigarettes either every day or some days to the
following survey question:


“Do you now use e-cigarettes every day, some days, or not at all?”

Ever e-cig users were defined as those having responded using e-cigarettes even one
time in the past to the following survey question:


“Have you ever used an e-cigarette, even one time?”
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Sociodemographic predictors that were included in this study were age (18-44 years,
45-64 years, ≥ 65 years), gender (Men, Women), race (White, African American),
marital status (Married, Widowed, Divorced/Separated, Never married), region
(Northeast, Midwest, South, West), BMI (Normal, Overweight/Obese), smoking status
(Current smokers, Former smokers), current working status (Working, Not working),
place of employment (Private firm/Self-employed/self-employed, Federal/State/Local
government employee), currently smoking tobacco products other than cigarettes every
day or some days (Yes, No), currently using smokeless tobacco products every day or
some days (Yes, No), have tried quitting smoking in the past one year more than once
(Yes, No), and have tried quitting tobacco in the past one year more than once (Yes,
No). Current smokers were defined as those who ever smoked 100 cigarettes and are
currently smoking cigarettes either every day or some days. Former smokers were
defined as those who ever smoked 100 cigarettes and are not smoking cigarettes
currently. Further, smoked tobacco products other than cigarettes included cigars,
pipers, hookahs or water pipes, very small cigars, bidis or cigarillos. Smokeless tobacco
products included products that can be placed in the nose or mouth such as chewing
tobacco, snuff, snus, dip, or dissolvable tobacco.
Statistical analysis
Prevalence estimates for current e-cig users and ever e-cig users among individuals
with COPD were calculated using the survey sample weights in order to represent the
estimates at the national level. Further, descriptive statistics (weighted frequency, %,
std.error) were calculated to describe the sociodemographic predictors for current e-cig
users among individuals with COPD. The Rao-Scott Chi square test was employed to
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test the research hypothesis that no association existed between current e-cigs use and
sociodemographic variable categories in the selected population, and that the variable
analyzed would be statistically independent.
Bivariate and multivariable analysis were performed using logistic regression (PROC
LOGISTIC) to estimate the association between current e-cig users and
sociodemographic predictors among individuals with COPD. The logistic regression
model was intended to be parsimonious and hence, all the predictor variables for the
model were selected based on literature and of practical significance. All
sociodemographic variables that were used to study the descriptive characteristics were
included in bivariate and multivariable analysis.
There was a problem encountered while performing bivariate logistic regression
analysis. Some of the sociodemographic variables such as currently smoking tobacco
products other than cigarettes every day or some days (Yes, No), and currently using
smokeless tobacco products every day or some days (Yes, No), had a large amount of
missing values within each variable category. Due to the large number of missing
values, there were empty clusters and empty stratum in the bivariate analysis and the
variance estimation for such variables omitted those empty stratums, causing an output
with incorrect regression coefficients and odds estimates. Hence, for the multivariable
regression analysis, we decided to build three models; first by incorporating these
problematic variables and doing cluster analysis, second by deleting these problematic
variables and doing analysis without cluster, third by deleting these problematic
variables and doing analysis with cluster. The reason to build and study these three
models was to study the impact of these problematic variables and cluster analysis on
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the model output for the association between current e-cigs use and sociodemographic
predictors. Further, out of three models, model with the stable parameter output was
interpreted for the study association.
Prior to the building of these three multivariable models, a collinearity check among the
predictor variables was performed. Pearson correlation tests were employed using
PROC CORR procedure. Results found collinearity between two sociodemographic
predictors; have tried quitting smoking in the past one year more than once (Yes, No),
and have tried quitting tobacco in the past one year more than once (Yes, No). Pearson
correlation co-efficient for these two variables was 0.809 (P < 0.0001), indicating the
presence of collinearity between these two variables. Hence, based on variable
significance, the variable that measured quitting of tobacco in past one year was
retained and included in the final multivariable regression model, while the one
measuring quitting of cigarettes in past one year was deleted and was not included in
any further model analysis. Interaction terms were also tested in the model. However,
all of the interaction terms were found to be insignificant and hence, were not included
in the final multivariable model analysis.
Next, a Hosemer- Lemeshow goodness of fit test was conducted in order to check
whether the model we assumed was specified correctly and that there was no conflict
between data and the assumptions made by the model. P-values from this test vary
between 0 and 1, higher number indicating a better fit, while lower values would indicate
that model is not acceptable.79 For this study, a P- value of 0.9596 was obtained after
incorporating sociodemographic predictors, indicating good fit for the specified model
with the data.
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All statistical tests were performed in SAS version 9.4 with a two-sided significance of
0.05 level.
3.2: Results
Aim 1A: To estimate the prevalence for current e-cig users and ever e-cig users
among individuals with COPD
A total of 7,434,218 (3.10%) individuals were identified from the 2014 NHIS data who
reported of having been diagnosed with COPD according to their physicians. Further,
among individuals with COPD, around 642,848 (8.65%) individuals reported of using ecigs currently, while the rest 91.35% were not using e-cigs device currently. Next,
among individuals with COPS, around 1,793,828 (24.37%) reported of having used ecigs device in the past, while the rest 75.63% did not use them in the past. Table 3 and
Figure 1 represents the estimates by e-cig user category among individuals with
COPD. The chi-squared test results were also significant by e-cig user category
indicating that both; current e-cig users and ever e-cig users are statistically
independent.
Table 3: Prevalence estimates for current e-cig users and ever e-cig users among
individuals with COPD in the US; NHIS 2014 data estimates
E-cig user category
Current e-cig users
Yes
No
Ever e-cig users
Yes
No

Weighted
frequency (% )

Std. error
of percent

Rao-Scott
Chi-square
test

642,848 (8.65)
6,791,370 (91.35)
24.37
1,793,828 (24.37)
5,566,982 (75.63)

0.9557
0.9557

591.99
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P-value

<0.0001
1.2619
1.2619

108.38

Figure 1: Prevalence estimate chart for current e-cig users and ever e-cig users
among individuals with COPD
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Aim 1B: To identify the sociodemographic predictors for current e-cig users
among individuals with COPD
Sociodemographic predictors were examined among current e-cig users and having
diagnosed with COPD. Percentages for currently using e-cigs were found to be higher
among women (62%), whites (90%), between 45-64 years of age (57%), being
divorced/separated (36%), being overweight/obese (74%), currently not working (88%),
working for private firm or self-employed (78%), currently smoking cigarettes (68%),
currently not smoking tobacco products (81%), currently not using smokeless tobacco
products (65%), and have tried quitting tobacco in past one year for more than one
day(62%) (Table 4). Additionally, those who resided in the south region of the US were
the ones who were currently using e-cigs device in higher proportion (54%) in
comparison to the current e-cigs device usage from all other US regions (Figure 2). All
72

the sociodemographic variables were analyzed for the test for equal proportions with the
help of chi-square test. The test results were highly significant (P < 0.0001) among all
the current e-cig user variable categories indicating that there exist statistical
independence among each of the sociodemographic variables being tested.
Table 4: Sociodemographic characteristics for current e-cig users among
individuals with COPD
Sociodemographic
characteristics
Sex
Men
Women
Age (years)
18-44
45-64
>= 65
Race
White
African American
Marital Status
Married
Widowed
Divorced/Separated
Never married
BMI
Normal
Overweight/Obese
Region
Northeast
Midwest
South
West
Working status
Currently working
Currently not working
Type of employment
Private firm/Self-employed

Weighted N (% )

Std.
error

Rao-Scott
Chi-square
test

P-value

244,914(38.10)
397,934(61.90)

2.36
2.36

24.19

<0.0001

30,833(4.79)
366,213(56.96)
245,802(38.24)

0.1361
1.6599
1.6082

705.37

<0.0001

559,134(90.37)
59,551(9.62)

0.167
0.167

20429.99

<0.0001

165,885(27.75)
160,160(26.79)
214,300(35.85)
57,294(9.58)

2.24
1.13
1.37
1.21

101.78

<0.0001

164,999(26.02)
469,051(73.97)

2.48
2.48

72.62

<0.0001

61,233(9.52)
194,688(30.28)
346,413(53.88)
40,514(6.3)

0.4384
1.01
1.144
0.3511

1790.58

<0.0001

80,340(12.49)
562,508(87.5)

0.8029
0.8029

962.78

<0.0001

496,088(77.73)

1.32

304.51

<0.0001
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Federal/State/Local
government employee
Smoking status
Current smokers
Former smokers
Currently smoking tobacco
products other than cigarettes
every day or some days
Yes
No
Currently using smokeless
tobacco products every day
or some days
Yes
No
Tried quitting smoking past
one year more than one day
Yes
No
Tried quitting tobacco past
one year more than one day
Yes
No

142,095(22.26)

1.32

435,592(68.48)
200,410(31.51)

1.65
1.65

109.11

<0.0001

33,250(18.59)
145,521(81.4)

0.2249
0.2249

12123.58

<0.0001

38,502(35.43)
70,165(64.56)

0.19
0.19

5603.19

<0.0001

242,512(55.67)
193,080(44.32)

1.37
1.37

17.11

<0.0001

360,013(62.2)
218,717(37.79)

2.01
2.01

34.84

<0.0001

Figure 2: Percentage of adults with COPD who currently use e-cigs by region:
NHIS 2014 estimates
West, 6%

Northeast,
10%

Midwest, 30%
South,
54%
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Further, percentages of current e-cig users among individuals with COPD were
estimated by age and by gender status (Figure 3), and by race and by gender status
(Figure 4). Percentages for current e-cig device use was higher for individuals between
45-64 years of age in total and among whites in total. Percentages of current e-cig
users were higher for women over men among all different age groups (Figure 3) and
among both races (Figure 4). Next, percentages for e-cigs usage, both for current users
and ever users, were calculated by smoking status (Figure 5) and by cigarette quitting
status (Figure 6). Among current users and ever e-cig users (Figure 5), 68% and 77%
of them were currently smoking cigarettes, respectively. Similarly, among current e-cig
users and ever e-cig users (Figure 6), 56% and 58% of them have tried using these
devices to help them quit smoking respectively.
Figure 3: Percentage of adults with COPD who are currently using e-cigs by age
and gender: NHIS 2014 estimates
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Figure 4: Percentage of adults with COPD who are currently using e-cigs by race
and gender: NHIS 2014 estimates
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Figure 5: Percentage of adults with COPD who are currently using and have ever
tried using e-cigs by smoking status: NHIS 2014 estimates
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Figure 6: Percentage of adults with COPD who are currently using and have ever
tried using e-cigs by quitting smoking status: NHIS 2014 estimates
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Aim 1C. To examine the association between current e-cig users and
sociodemographic predictors among individuals with COPD
Bivariate logistic regression analysis results (Table 5) found that the current e-cig use
was significantly associated with age (P = 0.0155), with marital status (P = 0.001), with
region of residence (P = 0.0003), with smoking status (P < 0.0001), with working status
(P = 0.0147), with current use of smokeless tobacco products either every day or some
days (P < 0.0001), and with tobacco quitting status in past one year (P = 0.0001). The
odds of using e-cig device currently among individuals with COPD were higher for
individuals between 45-64 years of age (OR: 1.766; 95% CI: 1.119, 2.785), residing in
south (OR: 3.893; 95% CI: 1.990, 7.619), currently smoking cigarettes (OR: 3.051; 95%
CI: 1.963, 4.740), currently using smokeless tobacco products every day or some days
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(OR: 1.967; 95% CI: 1.50, 2.580), and among those who have tried quitting the use of
tobacco in past one year for more than one day (OR: 2.345; 95% CI: 1.525, 3.603). The
odds of using e-cigs device currently among individuals with COPD were also found to
be higher for women, with African American race, widowed, divorced/separated,
overweight/obese, working with private-firm/self-employed, currently smoking tobacco
products other than cigarettes every day or some days, and have tried quitting smoking
past one year more than once. However, the association was not statistically significant
at the significance level of 0.05.
Table 5: Characteristics associated with current e-cig use among COPD patient
population (bivariate logistic regression analysis). Significant results highlighted
in bold
Unadjusted analysis
Socio-demographic variables
Sex
Men
Women
Age (years)
18-44
45-64
>= 65
Race
White
African American
Marital Status
Married
Widowed
Divorced/Separated
Never married
BMI
Normal
Overweight/Obese
Region
Northeast
Midwest
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Odds
ratio
0.742

0.815
1.766

0.765

0.526
1.391
1.536

0.928

1.503
3.33

95% Wald CI

P-value

0.469,1.175
Reference

0.203

0.335, 1.985
1.119,2.785
Reference
0.289,2.027
Reference
0.249,1.113
0.724,2.675
0.822,2.868
Reference
0.575,1.498
Reference
0.557,4.055
1.522,7.290

0.0155
0.2471
0.0081
0.5903
0.5903
0.001
0.001
0.0612
0.0094
0.7602
0.7602
0.0003
0.2972
0.0494

South
West
Smoking status
Current smokers
Former smokers
Working status
Currently working
Currently not working
Type of employment
Private firm/Self-employed
Federal/State/Local government
employee
Currently smoking tobacco products other
than cigarettes every day or some days
Yes
No
Currently using smokeless tobacco products
every day or some days
Yes
No
Tried quitting smoking past one year more
than one day
Yes
No
Tried quitting tobacco past one year more
than one day
Yes
No

3.893

3.051

0.456

1.26

1.990,7.619
Reference
1.963,4.740
Reference
0.243,0.857
Reference
0.795,1.996

0.0008
<0.0001
<0.0001
0.0147
0.0147
0.3259
0.3259

Reference
0.1144
1.484

0.909, 2.424
Reference

0.1144
<0.0001

1.967

1.50, 2.580
Reference

<0.0001
0.4029

1.225

0.761,1.972
Reference

0.4029
0.0001

2.345

1.525,3.603
Reference

0.0001

Further, multivariate logistic regression analysis was performed to find out the
association between current e-cig use and sociodemographic predictors among
individuals with COPD (Table 6). Out of all the variables included in the final model, the
association between current use of e-cigs and having tried quitting tobacco in the past
one year for more than one day was found to be significant (OR: 2.042; 95% CI: 1.051,
3.971; results from the model with cluster analysis and with relevant variables). The
odds of using e-cigs device currently among individuals with COPD were also found to
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be higher for white men, with age over 65, widowed, divorced/separated,
overweight/obese, residing in south, currently not smoking cigarettes, currently not
working, and if working; then working for Federal/State/Local government employee.
However, the association was not statistically significant at the significance level of 0.05.
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Table 6: Characteristics associated with current e-cig use among individuals with COPD (Multivariate logistic
regression analysis). Significant results highlighted in bold
Socio-demographic variables

Adjusted analysis with cluster and with few variables
Odds ratio
95% Wald CI
P-value

Sex
Men
Women
Age (years)
18-44
45-64
>= 65
Race
White
African American
Marital Status
Married
Widowed
Divorced/Separated
Never married
BMI
Normal
Overweight/Obese
Region
Northeast
Midwest
South
West
Smoking status

0.762

0.432, 1.346
Reference

0.3491

0.74
0.789

0.193, 2.833
0.384, 1.623
Reference

0.7456
0.7423

1.211

0.801, 1.832
Reference

0.3639

0.613
1.932
1.298

0.317, 1.186
0.819, 4.557
0.695, 2.422
Reference

0.657

0.368, 1.172

1.242
1.975
2.33
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0.393, 3.928
0.873, 4.468
1.028, 5.283
Reference

0.0094
0.0016
0.0296
0.331

0.1549
0.1957
0.5786
0.3449
0.0965

Current smokers
Former smokers
Working status
Currently working
Currently not working
Type of employment
Private firm/Self-employed
Federal/State/Local government employee
Tried quitting tobacco past one year more than one
day
Yes
No
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0.546

0.239, 1.247
Reference

0.1509

0.589

0.323, 1.072
Reference

0.0833

0.975

0.539, 1.763
Reference

0.9326

2.042

1.051, 3.971
Reference

0.0353

3.3: Discussion
The COPD prevalence in the United States using the 2014 NHIS survey data was
estimated to be 3.10%. This estimate was slightly lower than the estimates in a similar
study conducted by Doney et al.80 According to this study, the estimated prevalence for
COPD was found to be 4.2% (95% CI: 4.0% to 4.3%). This study estimated the
prevalence among COPD individuals using 2004-2011 NHIS data and included only
working adults from age 40 years till 70 years old. The difference in the type of
population included in our study and the study by Doney et al. could be the main reason
in the differences in the prevalence estimates. The prevalence is usually higher among
a working population, where it is attributable mainly due to occupational exposure.81
Further, in a study conducted by CDC, the age adjusted total prevalence among adults
aged 18 and over for chronic bronchitis was found to be 3.6%, while the age adjusted
prevalence for emphysema was found to be 1.3% for the year 2015. These estimates
came from the NHIS survey date and were very similar to the estimates from our
study.82
The prevalence estimates for current e-cig users and ever e-cig users among
individuals with COPD were found to be 8.65% and 24.37% respectively. To our
knowledge, this is the first study to report the prevalence for current and ever e-cig
users among individuals with COPD. All other studies have reported prevalence for
current and ever e-cig users among general population residing in the US.38 The
estimates in the study by Syamlal G. et al. comes from the same year and same data
source as ours with the only difference in the study population being evaluated. In the
study findings by Syamlal G. et al., the prevalence of ever e-cig users among US
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working adults aged ≥ 18 years was found to be 12.6%. While for this study, the
prevalence of ever e-cig users among COPD adults were two times higher than the
study estimate by Syamlal G. et al. Similarly, the prevalence of current e-cig users
among general population was 3.7%, while for this study it was nearly two times higher
among COPD individuals. The differences in these estimates indicates a higher use of
e-cig devices among disease individuals than the general population. Since e-cig
devices have been encouraged to help in quitting smoking, and are also marketed as an
alternative to smoking in places where tobacco smoking is prohibited,25 the uptake for
these devices may have increased among disease population either for trying to quit
smoking or as an alternative to smoking in the places where it is prohibited.
Further, descriptive analysis results found the percentage of current e-cigs use among
COPD adult individuals was higher among women (62%), among whites (90%), among
individuals between 45-64 years of age (57%), among current smokers (68%), and
among those who have tried quitting smoking in the past for more than one day (62%).
The estimates were in agreement with the results from the study done by Schoenborn
et al.,83 where the proportion of current e-cig users among general adult population
were higher among current smokers (16%) and among those who had tried quitting
smoking in the past (22%) in comparison to former smokers (2%) and never smokers
(0.4%). While our study results were not in agreement with the estimates of current ecig users among general population by gender, by race and by different age groups.
The proportion of current usage for e-cig devices among the general population were
found to be same for men and women, and higher among non-Hispanic American
Indian Alaska Native adults.
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The reason for such observed differences in e-cigs usage could be due to the fact the
prevalence of COPD among women is higher than in men and there exists differences
in the management to this disease.84 Also, tobacco users among women have
increased in comparison to men and they have greater difficulties in quitting smoking.
This might explain the higher use of e-cig devices among women in comparison to
males. Also as the prevalence of COPD is higher among individuals with age 45 and
above, among those unemployed and among those who are divorced/separated, this
again may be correlated with higher usage of e-cig devices in present.11
Further, the results from bivariate logistic regression analysis found an association for
the current use of e-cigs with those currently smoking cigarettes, have tried quitting
smoking in the past, and are currently using smokeless tobacco products. These
estimates were in agreement to the findings from the study by Schoenbron et al. This
indicates the possible connection for current smokers with COPD trying to use e-cigs
devices for quitting smoking.
This study possesses several weaknesses. First, since the prevalence estimates for
COPD were based on the self-reported diagnoses by physician and as NHIS doesn’t
collect the information related to spirometry or any other medical or laboratory data, the
estimates for COPD may be under- or over-reported. Second, the prevalence estimates
for current and ever e-cig users were also based on the self-report and have not been
validated like self-reported smoking status. Hence, it questions the accuracy for selfreported e-cigs use. Third, since NHIS data doesn’t include institutionalized individuals,
it misses out the sections of population such as military personnel, and older adults
living in nursing homes and other long-term care facilities. This may further lead to
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under or over-estimates for COPD, current and ever e-cig usage.85 Fourth, due to small
sample sizes among subpopulations, it restricted the precision of estimates. Fifth,
because of the cross-sectional study design, and estimates based on the annual
sample, results cannot be seen as causal. Finally, NHIS data possess the potential for
self-selection bias. The participation rate for the survey respondents for the year 2014
was only 58.9%. Since this data doesn’t capture the information from non-respondents,
it is difficult to tell whether the survey respondents differed from non-responders in a
significant manner.
However, this study possess many strengths. First, to our knowledge, this is the first
study to estimate the prevalence, identify characteristics and asses the association
between current e-cig users and sociodemographic predictors among individuals with
COPD. Second, the study was performed using the large sample size, population-based
data among non-institutionalized civilian individuals. Hence the results from this study
may be generalizable to the COPD disease population in the US. Additionally, since
NHIS survey data have been utilized for research purpose and in policymaking, the
results from this study can be used as point of reference for further studies or in
healthcare decision making.

86

Chapter 4: Specific Aim 2
Aim 2: To examine the predictors and estimate the total healthcare cost among
current smokers with COPD in the US
D. To examine the sociodemographic and clinical characteristics among current
smokers with COPD
E. To estimate the unadjusted total, direct and indirect healthcare cost among current
smokers with COPD
F. To estimate the adjusted total, direct and indirect healthcare cost among current
smokers with COPD
4.1: Methods
Design: Retrospective, cross-sectional design
Data
The Medical Expenditure Panel Survey (MEPS) data was utilized for this study. This
dataset provides nationally representative estimates of the US non-institutionalized
civilian population, with oversampling of blacks and Hispanics.86 The survey data is
collected through in-person interviews of families and individuals, their medical
providers, and employers in the US and provides information on sociodemographic and
economic characteristics, employment, income, health status, health insurance
coverage, health conditions, payments and charges, medical services utilization, access
to care, and medical conditions and procedures that were self-reported by the
participants. The survey consists of three main components: household component
(HC), medical provider component, and insurance component. For this study, HC files
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were utilized. Data from the years 2012 and 2013 were used for this study. Data from
both years were aggregated by using the common variance structure within MEPS
complex survey design in order to ensure compatibility and comparability of study
variables and to increase the precision of the estimates.87,88
Study population
The study population consisted of US non-institutionalized civilian population with age ≥
18 years, and being alive during the study period. Further, we included only those
individuals who self-reported of having diagnosed with COPD. COPD status were
identified using the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes 491 (chronic bronchitis), 492 (emphysema) and 496
(chronic obstructive airway disease, not elsewhere classified) from the medical
conditions file. The medical conditions and procedures self-reported by survey
participants are professionally coded to fully specified 5-digit ICD-9-CM codes. To
protect participant’s confidentiality, MEPS data collapses these 5-digit ICD-9-CM codes
to 3-digit ICD-9-CM codes.89 Our pooled sample consisted of 3,668 adults 18 years and
older and alive during the calendar year, representing an annually weighted population
of 18,936,800. The average response rate for participants from both years was 54.55%
(52.8% - 56.3%).90
Study variables
Our main independent variable for this study was current smoking status among the
survey participants. MEPS captures this information by asking participants whether they
currently smoke or not. The response to this survey questionnaire was categorized as
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Yes/No. Moreover, relevant sociodemographic and clinical variables were also included
in this study based on the Anderson Behavior and Utilization Model for Health Service
Use to identify the potential independent factors related to total healthcare cost.91
Variables were classified into three major components: predisposing factors, enabling
factors and need factors. Individual predisposing factors included age in years (18-44,
45-64, 65+), gender (male, female), race/ethnicity (white, African-American, Latino, and
other), marital status (married, widowed, separated/divorced, and never married), and
census defined region categories (Northeast, Midwest, South, West). Enabling factors
included were income (poor, near poor, middle income, and high income according to
the federal poverty line), type of health insurance (private, public, and uninsured)
education (less than high school, high school, and college or more), employment status
(employed and not employed). Need factors included were participant’s clinical
characteristics such as perceived physical health status (excellent/very good, good, and
fair/poor), Body Mass Index status (underweight, normal, overweight, and obese),
number of chronic conditions (≥ 1, none), presence of particular comorbid conditions.
Comorbid conditions included were presence of clinical conditions such as
cardiovascular and other circulatory disorders, depression and other mental disorders,
diabetes and other endocrine disorders, and arthritis and other musculoskeletal
disorders.
The key dependent variable for this study was the total healthcare cost per person per
year, which included both direct and indirect cost. Direct costs are the healthcare costs
associated with direct patient-care services.92 They include hospital inpatient, physician
inpatient, physician outpatient, emergency department outpatient, nursing home care,
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hospice care, rehabilitation care, specialists’ and other health professionals’ care,
diagnostic tests, prescription drugs and drug sundries, and medical supplies. The
source of this payment includes direct payment from individuals, through private
insurance, through Medicaid, through Medicare and other sources for each calendar
year.93 For this study, direct costs were classified as inpatient, outpatient, prescription,
emergency room, and other. Other costs included home health, vision, hearing devices,
prosthesis, durable medical equipment, disposable supplies, orthopedic items,
ambulance services, alterations/modifications, bathroom aids, medical equipment, and
other miscellaneous items that were rented, purchased, or obtained during the study
timeline. Indirect cost refers to the costs associated with the impact of disease on
patients or caregivers economic output.94
Indirect costs were estimated using the human capital approach which assumes
productivity to be valued at the individual’s market earnings.94 Productivity loss
(morbidity) consisted of the work days missed to stay in bed due to COPD. Hourly wage
for patients were multiplied by 8 (assuming 8 hours work day) to get the daily wage.
This was then multiplied by the number of workdays missed by those with COPD in
order to calculate the total productivity loss due to COPD. In this study indirect
productivity loss due to mortality were not examined as we included only those patients
that were alive during the calendar year. Total healthcare costs were then calculated by
summing both direct and indirect healthcare cost. All healthcare cost data were adjusted
to 2016 dollar value using the healthcare consumer price index for medical care
services obtained from the Bureau of Labor Statistics.95
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Statistical analysis
Prevalence estimates for current smokers and non-current smokers among individuals
with COPD were calculated using the survey sample weights in order to represent the
estimates at the national level. Further, descriptive statistics (weighted frequency, %,
std.error) were calculated to describe the sociodemographic and clinical characteristics
among current and non-current smokers with COPD. Differences in proportion of
individuals for each predisposing, enabling and need factors were also reported
between both groups using Rao-Scott Chi square test at the significance level of 0.05.
Further, unadjusted annual mean total, direct and indirect healthcare cost for current
smokers and non-current smokers were calculated among individuals diagnosed with
COPD. To estimate the adjusted annual mean total, direct and indirect healthcare cost,
an econometric or incremental approach was used. This approach estimates the
difference in cost between a cohort of current smokers with COPD and a cohort of noncurrent smokers without COPD. This approach is most appropriate with a large, national
dataset and is used for risk factors and diseases with several comorbidities. Incremental
healthcare cost were estimated using two-part model. Two-part models are used when
an outcome consists of a large number of zero outcomes and a group of nonzero
outcomes, resulting into the data that is highly skewed to right.96 In modeling of
healthcare cost, usually some patients have zero costs, while the rest have positive
costs that are often heavily skewed to the right. Hence, the two-part model (mixed
discrete-continuous) accounts for the observations having no cost (ie, 0 expenditures)
and accurately estimates the incremental healthcare cost for current smokers compared
to noncurrent smokers among individuals with COPD.97 In the first stage, a probit model
was used to evaluate the probability of having a 0 versus positive healthcare cost. In the
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second stage, a generalized linear model (GLM) with a log-link is assessed conditional
on cost for those having a positive healthcare cost. In the adjusted model, we controlled
for all sociodemographic and clinical characteristics. Post-regression margins provide
estimates for incremental total, direct and indirect health care cost for current smokers
compared to non-current smokers among individuals with COPD.
All of the descriptive analyses were carried out using SAS version 9.4 (SAS Institute
Inc, Cary, NC), whereas two-part model analyses were carried out using the ‘twopm’
command in Stata (Stata-Corp, College Station, TX). Post regression, estimates for
incremental healthcare cost were derived using the ‘‘margins’’ command in Stata. All
our analyses accounted for clustering, stratification, complex survey design, and
sampling weights to evaluate the national healthcare cost estimates for current smokers
among individuals with COPD. Further, in our analysis we divided the analytic sampling
weight variable by aggregated number of years to represent the average population size
per year.98
4.2: Results
Aim 2A. To examine the sociodemographic and clinical characteristics among
current smokers with COPD
A total of 18,936,800 (12.3%) individuals with age 18 years and above were identified
from the 2012-2013 MEPS data who were diagnosed with COPD and were alive during
the study period. Approximately 22% of them were currently smoking, while the rest
78% were not smoking during the time of the interview (Figure 7). Descriptive analysis
for sociodemographic and clinical characteristics for current smokers and non-current
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smokers among individuals with COPD revealed that there were significant statistical
differences between both groups when tested at 0.05 level of significance. Further,
among current smokers with COPD, percentages for current smokers were higher
among women (59.14%), with race other than white/black/Latino (66.47%), between 4564 years of age (47.81%), married (38.41%), having college or higher degree (39.78%),
with poor/near poor income (52.82%), unemployed (58.49%), with private insurance
(46.62%), residing in south (39.18%), being obese (43.15%), with perceived physical
health status as fair/poor (46.39%), having 1 or more chronic conditions (70.27%),
having diagnosed with arthritis and other musculoskeletal disorders (53.72%), and
having diagnosed with cardiovascular and other circulatory disorders (50.29%). (Table
7 and Table 8).
Figure 7: Percent of COPD individuals by current smoking status; MEPS 20122013 data estimates
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Table 7: Description of sociodemographic characteristics among COPD patient population by current smoking
status; Medical Expenditure Panel Survey 2012-2013
Sociodemographic
variables

Age
18-45
45-64
65+
Gender
Women
Men
Race/Ethnicity
White
Blacks
Latino
Other
Marital status
Married
Widow
Separated/Divorced
Never married
Education status
< High school
High school
College or more
Income FPL
Poor
Near Poor
Middle Income
High Income

COPD sample
population
Weighted N
18,936,800

Currently
smoking
Weighted N (% )
3,901,575(2.7)

Not currently
smoking
Weighted N (% )
13,653,006(9.60)

6,600,000
6,980,000
5,360,000

1,340,000(34.26)
1,870,000(47.81)
700,000(17.93)

4,680,000(34.24)
4,600,000(33.70)
4,380,000(32.06)

11,900,000
6,990,000

2,310,000(59.14)
1,590,000(40.86)

8,760,000(64.15)
4,890,000(35.85)

4,870,000
694,000
606,000
12,800,000

1,120,000(28.58)
119,000(3.05)
73,987(1.90)
2,590,000(66.47)

3,510,000(25.69)
513,000(3.76)
493,000(3.61)
9,140,000(66.94)

9,220,000
1,880,000
3,500,000
4,340,000

1,500,000(38.41)
365,000(9.35)
1,150,000(29.55)
885,000(22.69)

7,140,000(52.31)
1,400,000(10.23)
2,130,000(15.60)
2,990,000(21.87)

3,970,000
4,200,000
10,200,000

1,260,000(33.34)
1,020,000(26.88)
1,510,000(39.78)

2,300,000(17.35)
2,930,000(22.09)
8,030,000(60.56)

3,130,000
3,640,000
5,390,000
6,770,000

1,150,000(29.56)
908,000(23.26)
1,090,000(27.94)
750,000(19.24)

1,770,000(12.97)
2,500,000(18.30)
3,910,000(28.61)
5,480,000(40.12)
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chisqval Chisq
pvalue

Significance

160.411

0.000
0.000

***
***

0.000
0.051

***

85.600

0.000
0.090

***

49.558

331.685

0.000
0.000

***
***

272.587

0.000
0.000

***
***

410.065

0.000
0.000

***
***

Employment status
Employed
9,430,000
1,620,000(41.51)
7,090,000(51.95)
1.471
0.225
Not employed
9,510,000
2,280,000(58.49)
6,560,000(48.05)
0.000
Health insurance type
Private
11,800,000
1,820,000(46.62)
9,220,000(67.51)
0.000
Public
5,450,000
1,500,000(38.53)
3,520,000(25.75) 266.278 0.000
Uninsured
1,650,000
580,000(14.86)
919,000(6.73)
Census region
Northeast
3,890,000
716,000(18.53)
2,790,000(20.46)
0.000
Mid-west
4,200,000
1,080,000(27.86)
2,850,000(20.90)
46.091 0.004
South
6,930,000
1,530,000(39.18)
4,940,000(36.21)
West
3,920,000
577,000(14.79)
3,060,000(22.43)
Asterisks represent significant group differences in healthcare cost, on the basis of chi-square test.
*.01 # P < .05, **.001 # P < .01, ***P < .001.

***
***
***

***
**

Table 8: Description of clinical characteristics among COPD patient population by current smoking status;
Medical Expenditure Panel Survey 2012-2013
Sociodemographic
variables

Physical health status
Excellent/very good
Good
Fair/poor
Number of chronic
conditions
>=1
None
Selected
comorbidities

COPD sample
population
Weighted N
18,936,800

Currently
smoking
Weighted N (% )
3,901,575(2.7)

Not currently
smoking
Weighted N (% )
13,653,006(9.60)

chisqval Chisq
pvalue

Significance

7,410,000
5,810,000
5,720,000

855,000(21.90)
1,240,000(31.71)
1,810,000(46.39)

5,950,000(43.59)
4,200,000(30.73)
3,510,000

218.984

0.000
0.000

***
***

12,500,000
6,410,000

2,740,000(70.27)
1,160,000(29.73)

9,050,000(66.27)
4,600,000(33.73)

**

6.973

0.008
0.143
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Cardiovascular and
other circulatory
disorders
Yes
9,180,000
1,960,000(50.29)
6,710,000(49.17)
0.000
27.552
No
9,750,000
1,940,000(49.71)
6,940,000(50.83)
0.727
Depression and other
mental disorders
Yes
6,610,000
1790,000(45.84)
4,430,000(32.46)
0.000
143.172
No
12,300,000
2,110,000(54.16)
9,220,000(67.54)
0.000
Diabetes and other
endocrine disorders
Yes
3,240,000
761,000(19.51)
2,350,000(17.23)
0.000
26.778
No
15,700,000
3,140,000(80.49) 11,300,000(82.27)
0.293
Arthritis and other
musculoskeletal
disorders
Yes
8,960,000
2,100,000(53.72)
6,400,000(46.85)
0.218
1.515
No
9,970,000
1,810,000(46.28)
7,260,000(53.15)
0.012
BMI categorization
Under weight
278,000
75,402(1.96)
191,000(1.43)
0.000
Normal
5,150,000
1,040,000(27.14)
3,610,000(26.90)
0.256
28.170
Over
5,730,000
1,070,000(27.75)
4,270,000(31.80)
Obese
7,440,000
1,660,000(43.15)
5,350,000(39.87)
Asterisks represent significant group differences in healthcare cost, on the basis of chi-square test.
*.01 # P < .05, **.001 # P < .01, ***P < .001.
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***

***
***

***

*
***

Aim 2B. To estimate the unadjusted total, direct and indirect healthcare cost
among current smokers with COPD
The unadjusted cost for current smokers and non-current smokers among individuals
with COPD were calculated using the two-part regression model. The unadjusted
annual mean per person total, direct and indirect healthcare cost among current
smokers with COPD were $12,555.20 (SE: $588.30), $11,563.60 (SE: $556.30), and
$991.60 (SE: $119.50) respectively (Table 9), while the unadjusted annual mean per
person total, direct and indirect healthcare cost for non-current smokers with COPD
were $10,968.60 (SE: $558.40), $10,054.30 (SE: $527.60), and $914.30 (SE: $168.60)
respectively (Table 9). The unadjusted cost were higher among current smokers with
COPD in comparison to those not-currently smoking (Figure 8). However, only
outpatient and emergency room cost were significantly higher for current smokers with
COPD in comparison to non-current smokers with COPD. Among current smokers with
COPD, direct healthcare cost comprised of the major total cost (88.23%), where bulk of
those cost came from outpatient (33.17%) and prescription (32.49%), followed by
inpatient (28.76%) cost (Table 9). Healthcare cost were also calculated by age and
gender, as men and women use healthcare resources differently to meet their disease
demands. The unadjusted total, direct and indirect healthcare costs were found to be
higher for women when compared to men among current smokers with COPD (Figure
9). Among men, cost were higher for individuals with age 65 years and above, while for
women, total cost were higher for individuals between 45 and 64 years of age (Table
10).
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Figure 8: Unadjusted total, direct and indirect healthcare cost among individuals
with COPD by current smoking status; Medical Expenditure Panel Survey 20122013
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Figure 9: Unadjusted healthcare cost for current smokers among individuals with
COPD by age and gender status; Medical Expenditure Panel Survey 2012-2013
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Table 9: Unadjusted annual mean (SE) healthcare cost per person by current smoking status among individuals
with COPD; Medical Expenditure Panel Survey 2012-2013 estimates
Healthcare Cost
Direct Cost
Inpatient
ER
Outpatient
Prescription
Others
Indirect Cost
Total

Unadjusted annual mean (SE) healthcare cost per patient
Current smokers
Not currently smoking
Mean (SE)
95% CI
Mean
95% CI
$11,563.60 ($556.30) [10466.8 , 12660.4]
$10,054.30($527.60)
[ 9013.9 , 11094.6]
$3,057.90 ($300.50)
[ 2465.3 , 3650.4]
$2,182.20($305.50)
[ 1579.8 , 2784.6]
$366.00 ($29.40)
[ 308.1 , 423.9]
$545.50($55.20)
[ 436.8 , 654.3]
$3,756.30 ($274.70)
[ 3214.6 , 4297.9]
$2,622.90($200.20)
[ 2228.3 , 3017.6]
$3,325.50 ($209.40)
[ 2912.6 , 3738.4]
$3,805.60($268.20)
[ 3276.8 , 4334.5]
$1,058.00 ($98.70)
[ 863.4 , 1252.5]
$897.90($150.50)
[ 601.3 , 1194.6]
$991.60 ($119.50)
[ 755.8 , 1227.4]
$914.30($168.60)
[ 581.5 , 1247.0]
$12,555.20 ($588.30) [11946.1 , 14265.8]
$10,968.20($558.40) [10315.1 , 12517.2]

Table 10: Unadjusted annual mean (SE) healthcare cost per person among current smokers with COPD by age
and gender; Medical Expenditure Panel Survey 2012-2013 estimates
Healthcare cost by
different age group
Total cost
18-44
45-64
65+
Direct cost
18-44
45-64
65+
Indirect cost
18-44
45-64

Unadjusted annual mean (SE) healthcare cost per patient
Men
Mean (SE)
95% CI
Mean
$5,091.53($1,147.99)
$12,164.00 ($1,592.15)
$18,142.00($1,328.02)

[2828.08, 7354.99] $7,689.67 ($705.67)
[6298.32, 9081.01]
[9025.18, 15303.5] $17,359.00($1,771.08) [13867,20851.33]
[15523.16, 20760] $16,384.00($1,216.57) [13985.4,18782.7]

$4,479.89 ($1,106.14) [2298.96, 6660.81] $6,379 ($613.10)
$10,651.00($1,499.10) [7695.01,13606.45] $15,407 ($1,661.38)
$16,258.00 ($1,235.13) [13822.38,18692.8] $14,678 ($1,159.42)
$646.85 ($177.09)
$1,656.46($551.34)

Women
95% CI

[297.48, 996.23]
[568.74, 2744.17]
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$898.62($227.17)
$1,086.89 ($153.73)

[5170.28, 7587.94]
[12131.68,18683]
[12392,16964.29]
[450.45, 1346.80]
[783.61, 1390.17]

Aim 2C: To estimate the adjusted total, direct and indirect healthcare cost among
current smokers with COPD
The adjusted cost for current smokers and non-current smokers among individuals with
COPD were calculated using the two-part regression model. The adjusted incremental
total annual average cost among current smokers with COPD were significantly higher
by $1,811.70 (P = 0.015) (Table 11) when compared to those not currently smoking.
Further, the adjusted incremental total annual average cost among current smokers with
COPD were higher significantly for women ($1,719.80), with age 65 and above
($5,134.03), having college or higher degree ($3,780.46), unemployed ($3,618.21),
covered through private insurance ($7,259.76), having perceived physical health status
as fair/poor ($8,568.66), with 1 or more chronic conditions ($3,579.41), having
depression and other mental disorders ($4,070.06), having diabetes and other
endocrine disorders ($3,067.80), and having arthritis and other musculoskeletal
disorders ($2,593.07). (Table 11). The adjusted total, direct and indirect healthcare cost
among current smokers with COPD were $12,441.67, $10,972, and $145.13
respectively (Table 12). Out of the total cost estimates, direct cost comprised major
part of the cost (88%), with majority of those direct cost coming from prescription
(31.63%), outpatient (31%), and inpatient cost (25.65%). Adjusted healthcare cost were
also calculated by age and gender status. The adjusted incremental total, direct and
indirect healthcare cost were found to be higher for women ($1,901) among current
smokers with COPD in comparison to non-current smokers with COPD (Table 13). The
adjusted incremental total, direct and indirect healthcare cost were found to be higher
for men ($1,649) among current smokers with COPD in comparison to non-current
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smokers with COPD (Table 13). Among men, cost were higher for individuals with age
65 years and above ($2,049). Among women, cost were higher for individuals with age
over 45 years ($1,800).
Table 11: Two-part regression model: incremental total healthcare cost by current
smoking status among US adults with COPD accounting for sociodemographic
and clinical characteristics adjusted to 2016 dollars
Adjusted annual mean (SE) healthcare cost per COPD
patient
Incremental cost
95% CI
P-value
Constant
$12441.67
$11684.23
$13199.11
0
Key independent variable
Not smoking
Reference
Currently smoking
$1,811.70
$345.47
$3,277.93
0.015
Age
18-45
Reference
45-64
$3,355.68
$1,546.24
$5,165.13
0
65+
$5,134.03
$3,081.91
$7,186.15
0
Gender
Women
$1,719.80
$92.36
$3,347.24
0.038
Men
Reference
Race/Ethnicity
White
$1,590.79
-$1,434.62
$4,616.21
0.303
Blacks
$2,862.69
-$2,042.96
$7,768.35
0.253
Latino
Reference
Other
$2,013.74
-$700.13
$4,727.63
0.146
Marital status
Married
-$874.74
-$3,224.01
$1,474.51
0.466
Widow
$416.87
-$2,663.83
$3,497.59
0.791
Separated/Divorced
$9.52
-$3,114.56
$3,133.60
0.995
Never married
Reference
Education
< High school
Reference
High school
$238.95
-$1,476.68
$1,954.59
0.785
College or more
$3,780.46
$2,033.76
$5,527.63
0
Income FPL
Poor
$864.69
-$2,285.89
$4,015.29
0.516
Near Poor
$468.69
-$1,989.07
$2,926.47
0.641
Middle Income
-$1,043.07
-$2,925.42
$839.28
0.302
High Income
Reference
Employment status
Sociodemographic and
clinical variables
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Employed
Not employed
Health insurance type
Private
Public
Uninsured
Census region
Northeast
Mid-west
South
West
Physical health status
Excellent/very good
Good
Fair/poor
Number of chronic
conditions
>=1
None
Selected comorbidities
Cardiovascular and other
circulatory disorders
Yes
No
Depression and other
mental disorders
Yes
No
Diabetes and other
endocrine disorders
Yes
No
Arthritis and other
musculoskeletal disorders
Yes
No
BMI categorization
Under weight
Normal
Over
Obese

Reference
$5,577.44

$3,618.21

$1,717.67

$7,259.26
$3,980.84

$5,159.26
$1,992.71

$9,359.26
$5,968.98
Reference

0
0

$635.74

-$2,166.25

0.629

-$1,235.81
-$1,977.63

-$3,120.61
-$4,010.92

$3,437.74
Ref
$648.99
$55.65

$3,600.34
$8,568.66

$1,957.57
$6,830.77

Reference
$5,243.12
$10,306.55

$3,579.41

$877.72

$6,281.10
Reference

0.009

$1,092.97

-$1,310.74

$3,496.69
Reference

0.373

$4,070.06

$2,554.88

$5,585.23
Reference

0

$3,067.80

$1,118.85

$5,016.74
Reference

0.002

$2,593.07

$381.36

$4,804.77
Reference

0.022

$1,863.42
$974.94
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0

0.23
0.057

0
0

Not estimable due to small sample size
Reference
-$26.97
$3,753.81
0.053
-$692.88
$2,642.77
0.252

Table 12: Adjusted annual mean (SE) healthcare cost per person among current
smokers with COPD; Medical Expenditure Panel Survey 2012-2013 estimates
Adjusted
Cost estimates

Mean

Total Cost

$12,441.67

$386.88 [$11684.23,$13,199.11]

Direct Cost

$10,972.93

$359.75

[$10267.11,$11678.7]

Inpatient

$2,814.72

$205.18

[$2412.58, $3216.86]

ER

$403.41

$23.40

[$357.54, $449.27]

Outpatient

$3,365.52

$173.22

[$3026.00, $3705.03]

Prescription

$3,469.96

$167.42

[$3141.81, $3798.11]

Others

$976.01

$62.47

[$853.57, $1098.46]

Indirect Cost

$145.13

$16.24

[$113.28, $176.97]

SE

95% CI

Table 13: Adjusted incremental annual mean (SE) total healthcare cost per person
among current smokers with COPD by age and by gender in comparison to
nonsmokers; Medical Expenditure Panel Survey 2012-2013 estimates
Total cost estimates by
gender and by age

Mean

SE

95% CI

Men

$1649.45

$693.92

[$289.39, $3009.52]

18-44

$993.769

$486.30

[$40.62, $1946.91]

45-64

$1538.51

$721.41

[$124.56, $2952.46]

65+

$2049.35

$908.14

[$269.43,$3829.28]

Women

$1901.00

$785.64

[$370.06, $3431.93]

$1418.23

$652.28

[$139.77, $2696.69]

$1797.23

$823.73

[$182.73, $3411.72]

$1811.55

$813.35

[$217.40, $3405.70]

18-44
45-64
65+
4.3: Discussion

This study aimed to estimate the total healthcare costs among current smokers with
COPD in comparison to non-smokers with COPD. The unadjusted and adjusted total
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healthcare costs among current smokers with COPD were found to be higher by $1,586
and $1,811, respectively in comparison to non-smokers with COPD. The total
incremental healthcare costs among current smokers with COPD for this study was
estimated to be $7.06 billion per year. The average adjusted total healthcare costs
among current smokers with COPD were estimated to be $14,252 per patient per year.
Direct healthcare costs comprised of the major component to the total healthcare costs
spending. Among direct healthcare costs, outpatient and prescription costs consisted of
the major percentages, followed by inpatient, ER and other healthcare costs.
Further, the unadjusted and adjusted total healthcare costs were found to be higher
among women in comparison to men. Additionally, the unadjusted and adjusted total
healthcare costs were found to be higher among individuals with age 65 & above in
comparison to individuals between 18 and 64 years of age group. The reason might be
due to the presence of multiple chronic conditions among this age group and the costs
associated in treating those chronic conditions.
The prevalence for COPD using 2012-2013 MEPS survey data was estimated to be
12.3%. This estimate was higher in comparison with the results using NHIS and BRFSS
database in this study. The prevalence estimates for COPD using NHIS and BRFSS
databases were found to be 3.1% and 6.3% respectively. Difference in prevalence
estimates might be due to the differences in sampling designs and data collection
procedures associated with each survey data. Although all of the three surveys captures
respondents self-report in order to measure health service utilization and health
characteristics, the differences in prevalence estimates might be due to difference in
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wordings of the survey questionnaire or differences in the understandings of survey
participants and also differences in the style of conducting survey.
To our knowledge this is the first in kind study that have estimated the adjusted and
unadjusted total healthcare cost among current smokers with COPD in comparison to
non-smokers with COPD. All of the studies till now have estimated healthcare costs
among COPD, but haven’t estimated the cost estimates separately for those who were
currently smoking cigarettes. Also, in our analysis we adjusted for all the relevant
sociodemographic and clinical characteristics that were thought to be of practical
significance. Further, all our costs estimates were calculated using two-part model
where we accounted for both zero and positive expenditures. In addition, the estimates
from this study are generalizable as the sample from the study was nationally
representative of the US institutionalized population.
However, this study have few limitations. First, due to cross-sectional nature of this
study, it doesn’t help establish temporality. It can only identify an association for
sociodemographic and clinical characteristics with total healthcare costs. In order to
establish casualty, it’s essential to conduct a longitudinal study design. Second, since
MEPS collects information on clinical condition through self-reported survey, it possess
threats related to self-recall bias and self-selection bias. Also, the information for this
survey comes from self-report, it may possess errors related to coding of clinical
conditions or can have misclassification bias, hence COPD prevalence estimates and
current smoking activity may be under reported or over reported. Third, although MEPS
identifies all pharmacy refills of individuals with COPD, it doesn’t capture the information
on over the counter medication use, hence prescription estimates could be
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underestimated. Finally, MEPS doesn’t capture the information for institutionalized
individuals. Hence, this may lead to underestimation of prevalence for COPD and
current smoking activity among disease population.
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Chapter 5
Aim 3: To estimate the economic impact of adopting e-cigarettes as a smoking
cessation tool among current smokers with COPD in the US
A: To estimate the 1-year and accumulated 5-year total healthcare cost savings
associated with E-cigarettes (e-cigs) use in comparison to smoking cessation therapies
among current smokers with COPD in the US
B: To estimate the 1-year and accumulated 5-year total healthcare cost savings by
gender associated with e-cigs use in comparison to smoking cessation therapies among
current smokers with COPD in the US
C: To estimate the 1-year and accumulated 5-year total healthcare cost savings by
different age groups associated with e-cigs use in comparison to smoking cessation
therapies among current smokers with COPD in the US
Design: An epidemiological cohort-markov model was developed following the
guidelines for Budget Impact Analysis—Principles of Good Practice: Report of the
ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.99
5.1: Methods
Budget impact (BI) analysis is a type of pharmacoeconomic evaluation that is used to
assess the changes in the healthcare spending when a new intervention is being
adopted or implemented into the healthcare organization or system.99 The advantage of
this methodology over other pharmacoeconomic evaluation techniques is that unlike
cost-effectiveness (CE) or cost-benefit (CB) analysis which looks at a representative
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individual or a cohort to estimate the cost and benefits associated with the new
intervention, BI looks at the current and future population of interest and estimates the
impact of introducing new intervention on short and long-term healthcare annual
budgets.99 The primary purpose of BI analysis is to provide information on the impact of
implementing a new technology on economic consequences into the current
organizational system addressing questions related to affordability of the new
intervention.99 The estimates for developing the BI model for this study were obtained
from the publicly available data sources and published research studies. Below are the
steps that were used to build the BI model following the guidelines as described by the
ISPOR task force.
Step 1: Characterizing the targeted population
The targeted population represents the number of individuals who will be eligible to
receive smoking cessation therapy before entering the BI model. To be eligible, the
targeted cohort of participants should be residing in the US, been diagnosed with
COPD, currently smoking cigarettes and have tried quitting smoking at least once in the
past. Such a population was identified using the publicly available data sources as
mentioned below:
a) Current US population: The current US population data was obtained from the
United States Census Bureau website.100 Adults of age 18 and above were only
included for this study as it is illegal to sell or supply tobacco products to minors. The
US population estimates were further stratified by different age groups and by gender in
order to explore the differences in healthcare utilization and costs based on these
factors.
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b) COPD diagnosed population (prevalence and incidence): Prevalence estimates
for individuals diagnosed with COPD were obtained from the 2015 Behavioral Risk
Factor Surveillance System (BRFSS) data. This cross-sectional survey is a federally
funded telephone survey conducted annually by the CDC. It collects information from all
50 states regarding modifiable risk factors for chronic diseases and other leading
causes of deaths.101 It uses a multistage cluster design and random digit dialing to
select a nationally representative sample of civilian, non-institutionalized adults aged
≥18. The data from each state are weighted to reflect the respondent’s probability of
selection and the age-by-sex or age-by-race/ethnicity-by-sex category in the population
of the state.102 Since 2011, BRFSS uses only one question to assess COPD
prevalence:
 “Have you ever been diagnosed with chronic obstructive pulmonary disease,
emphysema or chronic bronchitis?”
Participants having answered yes to the above question were identified as having
COPD. These estimates were also stratified by age and by gender. Prevalence
estimates were calculated using BRFSS sample weights in order to represent the
estimates at the national level and were obtained by using SAS version 9.4. The
BRFSS data source was used in estimating COPD prevalence for the targeted
population entering into the first year of the BI model. Starting from the second year,
COPD incidence estimates were used in building the targeted population up to the
period of 5-years. Incidence estimates for COPD were obtained from the report of
several studies and surveys conducted by the CDC which estimated the new cases of
COPD on the basis of the encounters from the emergency department visits and having
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COPD as a first-listed diagnosis.103,104,105 The COPD incident case estimates that were
considered in building the BI model are described in table 14 as below:
Table 14: Incidence estimates for COPD in total, by gender and by age group
status
Variable
Total
Gender
Male
Female
Age
25–44 years
44-65 years
≥ 65 years

Cases per 1000
population

Source

45.0
46.8
43.4
17.7
39.1
122.8

Afonso et
al., Mannino
et al, Rycroft
et al.

c) Current smokers: 2015 BRFSS data source was used to estimate the percentages
of current smokers among individuals with COPD. The BRFSS Survey captures this
information by asking survey participants the following questions:
 "Have you smoked at least 100 cigarettes in your entire life?"
 "Do you now smoke cigarettes every day, some days, or not at all?"
Participants having reported smoking at least 100 cigarettes in their lifetime and
reporting currently smoking "every day" or "some days" were classified as current
smokers. These estimates were also stratified by age and by gender and were obtained
using SAS version 9.4.
d) Have tried quitting smoking at least once in past one year: The final step in
identifying the targeted population was to obtain the percentages among current
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smokers with COPD who wanted to quit smoking and had actually tried quitting at least
once in the past one year. This represents the population who wants to quit smoking
actively and are ready to try any of the smoking cessation therapies for quitting. These
estimates were also obtained from 2015 BRFSS data, which asked participants the
following survey question:
 “During the past 12 months, have you stopped smoking for one day or longer because
you were trying to quit smoking?”
These estimates were further stratified by age and by gender. Figure 10 and Table 15
below depicts the flow chart and represents the overall steps involved in obtaining the
final targeted population. All our estimates were calculated using the BRFSS sampling
weights and all our analysis were performed using SAS version 9.4.
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Figure 10: Flowchart representing the steps involved in identifying the BI model targeted population

Targeted population flowchart

BRFSS 2015 estimates
Have tried quitting
smoking in past one
year
US 2015 estimates

Current smokers

63.36%

35.38%

Haven't tried quitting
smoking in past one
year

Doesn't smoke
currently

36.64%

Have COPD
6.24%
US Cesus bereau
population

64.62%

Don't have COPD
93.76%
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Table 15: Steps in identifying the targeted population for the BI model: analysis estimates using 2015 BRFSS
data
Targeted population
US 2015 census
estimates

Age group
in years
18-44
45-64
65 & above
Total
Age group in
years

Prevalence of COPD
Estimates by age and
gender

Percentage of current
smokers among
individuals with COPD
Estimates by age and
gender

Percentage of current
smokers with COPD who
have tried quitting
smoking in past one year
Estimates by age and
gender

18-44
45-64
65 & above
Total

Male
48.51%
34.00%
17.49%
100%
BRFSS 2015
estimates
(%)

8.55%
17.66%
16.60%
42.81%

Female

58,511,002
41,013,523
21,090,217
120,614,742

Total

45.17%
33.86%
20.97%
100%

57,435,875
43,052,457
26,670,635
127,158,967

Estimated
BRFSS 2015
population estimates (%)

Estimated
population

1,321,922
2,730,426
2,566,539
6,618,888

6.24%
1,643,512
3,778,687
3,416,898
8,839,099
35.38%

10.63%
24.44%
22.10%
57.17%

18-44
45-64
65 & above
Total

11.24%
22.91%
9.54%
43.69%

614,842
1,253,206
521,850
2,389,899

13.21%
31.13%
11.96%
56.30%

722,604
1,702,851
654,227
3,079,683
63.36%

18-44
45-64
65 & above
Total

11.48%
397,882
21.99%
762,145
7.97%
276,230
41.44% 1,436,258.31

14.65%
32.88%
11.00%
58.53%

507,750
1,139,579
381,246
2,028,576
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247,773,709

Total

15,461,079
15,461,079

5,470,129

5,470,129

3,465,874

Step 2: Selecting time horizon
The BI model for this study was developed from the societal perspective for a period of
5-years. Because of the short time period, healthcare costs in this model were not
discounted.
Step 3: Current and future treatment mix
Following the guidelines for smoking cessation therapies from the United States Public
Health Service, first-line agents recommended for smoking cessation are Varenicline,
Bupropion and Nicotine Replacement Therapies (transdermal nicotine patch, nicotine
gum, inhaler, lozenge, and/or nasal spray).57 These pharmacologic aids make it easier
for a smoker to quit tobacco smoking by helping them in reducing the symptoms of
nicotine withdrawal.60 Hence, the current treatment arm for this study consisted of the
mix of these recommended pharmacotherapies along with their recommended dose and
duration. Further, to this current treatment arm, e-cigs were added from the first year
onwards until the period of 5-year as a future treatment mix. Additionally, we also
compared e-cigs with no cessation alternative in order to evaluate the performance of ecig devices in the absence of any smoking cessation therapies and to estimate the total
cost savings associated with its use in comparison to no cessation alternative. The
detailed information for smoking cessation pharmacotherapies and e-cig devices
included in the BI model are provided as below:
Nicotine replacement therapy (NRT’s): NRT’s help in relieving nicotine withdrawal
symptoms by providing nicotine to the smokers without using tobacco. Three types of
NRT products that are currently available in the US without prescription includes
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lozenges, gums and patch, while other two (nasal spray and oral inhaler) are available
by prescription only.57 Long-acting nicotine patches are prescribed primarily to control
long-term abstinence, while rapidly-acting nicotine lozenges/gums are provided to help
relieve rapid acute cravings and withdrawal symptoms. The choice for this rapid-acting
will depend on the patient comorbidities and their preferences.57 For this study, nicotine
patches were considered as an option for smoking cessation in the BI model.
Varenicline: In 2006, the Food and Drug Administration approved the use of
Varenicline tartrate (Chantix) for its use in smoking cessation for the course of 12-weeks
and is available only by prescription.106 It is a partial agonist at the alpha-4 beta-2
subunit of the nicotine acetylcholine receptor where by binding to this receptor it helps in
reducing the symptoms of nicotine withdrawal.107 It also blocks nicotine from the smoke
to bind with this receptor and thereby reduces dependence on nicotine.
Bupropion: Bupropion was approved by the Food and Drug Administration in 1997 as
a smoking cessation pharmacotherapy drug that is available only by prescription. It
exerts its main effect through blocking the reuptake of dopamine and noradrenaline with
little serotonergic effect.108 It is available as an extended release anti-depressant pill
that helps in reducing nicotine withdrawal symptoms. Treatment duration can be
anywhere from 7 to 12 weeks long.
E-cigarettes: There are over 400 brands of e-cigs and nearly 7000 unique flavors
available for sale through internet.109 They are generally grouped into three categories:
cigalikes, eGos and mods.110 Cigalikes resemble conventional cigarettes with respect to
its shape and size. eGos are larger than cigalikes and have a removable tank to refill
nicotine e-liquid. Mods are the largest e-cig devices that have batteries that can lasts
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longer than the former two devices. Since Cigalikes claims to be a good substitute for
smoking, are comparatively cheaper and healthier, and are effective for use in smoking
cessation, this study mainly focused on Cigalikes e-cig brand for its use in smoking
cessation.109
Step 4: Determining efficacy
Smoking cessation therapy outcome selected for this study was the carbon monoxide
confirmed continuous smoking abstinence rate until 52-weeks. The annual abstinence
rate reflects the rates for individuals who were compliant with the recommended dose
throughout the treatment period and were able to be followed-up. Efficacy rates for
Varenicline, Bupropion, and NRT’s were obtained from the published randomized
controlled trials or meta-analyses studies. Rates for the e-cigs device were obtained by
taking the average efficacy estimate from studies included in the literature review. The
smoking cessation outcome considered in estimating the average efficacy estimate was
continuous smoking abstinence among current smokers over the period of 12-months.
We included 11 studies from the literature review that actually estimated smoking
cessation outcome. The average smoking abstinence rate at 52-weeks for e-cigs device
was estimated to be 21.08%(SD: 16.14; 95% CI: 11.94, 30.21), while the lower bound
and upper bound values for the e-cigs efficacy were estimated to be 11.94% and
30.21% respectively. Since the estimates came from different sources, sensitivity
analysis were conducted over upper bound and lower bound efficacy estimates. The
smoking cessation abstinence rates, therapy compliance rates, dose and duration for all
pharmacotherapies and e-cig devices are provided in table 17.
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Further, a markov model was developed that allowed individuals who failed to quit
smoking in the first year to be given a further chance to quit smoking. A maximum of
three quit attempts were allowed during a 5-year period.111 Also, for those who were
successful in quitting smoking, a relapse rate of 10% was assumed.112 Hence, a cohort
starting from the second year included both the population who failed to quit smoking in
the previous year and the population who relapsed to smoking after successful quit
attempt. This process was repeated for the next year until the end of 5-year period. The
markov model structure that was used in this study is depicted in figure 11 as below:
Figure 11: Markov model structure depicting the process of quitting among
smokers
Relapse
Success

Quit attempt

Smoking status

Failure

Step 5: Obtaining the market uptake rates
Market shares for current smoking cessation drugs and the e-cigs device were obtained
from a published market analysis research report.113 According to the report, the
smoking cessation and nicotine de-addiction market is divided into three main
components, which consists of drug therapy, NRT’s, and e-cigs. Drug therapy
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comprises of the prescribed smoking cessation products such as Varenicline and
Bupropion. The revenues generated from the sale of the smoking cessation and
nicotine de-addiction products were estimated to be $2,600 million dollars for the year of
2015. This report forecasted the future market shares for e-cigs and other smoking
cessation alternatives up to the year 2024. Results indicated that smoking cessation
market is going to expand and increase over the next few years where e-cig devices are
going to possess a large market share in comparison to the drug therapies and NRT’s.
For this study’s purpose, the market share for each alternatives were calculated in the
form of percentages from the forecasted sales. The market uptake rates for e-cig
devices in smoking cessation were considered from the years 2013 until the year 2017.
Table 16 below contains the information related to market share dynamics for the
smoking cessation alternatives in each of the 5-years of the model.
Table 16: Market place dynamics for smoking cessation therapies in each of the 5
years of the model113
Year

NRT's (% )

2013
2014
2015
2016
2017

40.91
44.00
42.86
41.94
42.86

Drug therapies
(Varenicline and
Bupropion) (% )
13.64
8.00
10.71
9.68
8.57

E-cigarettes (% )
45.45
48.00
46.43
48.39
48.57

Step 6: Determining drug costs
As the study was conducted from the societal perspective, drug retail prices were being
evaluated. For Varenicline, we assumed the 12-week course treatment dosed at 1mg
pill per day and the total costs for the smoking cessation treatment to be $567.82. For
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Bupropion, we assumed 12-week course treatment dosed at 200 mg pill per day and
the total cost for the smoking cessation treatment to be $191.76. Both Varenicline and
Bupropion retail prices were obtained from rxprice.com. Additionally, a one-time
physician visit cost for both of these prescription drugs was included and obtained from
the healthcare blue book. For NRT’s, we assumed the 8-week course treatment of
Nicoderm CQ patches. For individuals starting with Nicoderm CQ patches, we assumed
a first two weeks treatment with 21 mg nicotine clear patches, followed by two weeks
treatment with 14 mg nicotine clear patches and then by two weeks treatment with 7 mg
nicotine clear patches. NRT’s retail pricing were obtained from drugstore.com. The total
price for all the three prescription medications were calculated by multiplying per day
dose cost with total duration. For e-cigarettes, the average price for Cigalikes brand
were obtained through online websites. The average price of e-cigs from the five top
selling brands were being considered for this study. Table 17 below details information
on dose, duration, cost, compliance and efficacy rates for the smoking cessation
alternatives considered for this study.
Table 17: Information on dose, duration, cost, compliance and efficacy rates for
the smoking cessation alternatives considered in the BI model
Smoking-cessation
treatment alternatives
Varenicline114,115,116,117,118,

Value

Source

119

Dose
Duration
Smoking abstinence rate
at 52-weeks; % (SD)
Product compliance
Cost of therapy

22.5 (4.88)

Drug cost

$567.85

1 mg/day
12 weeks

84%
$827.85

119

Fiore MC, Ebbert JO
Taylor et al., Gonzales et al.,
Jorenby DE et al.
Tashkin DP et al

Rxprice.com

Physician visit cost

$260

Healthcare blue book

Bupropion116,117,118,119
Dose
Duration
Smoking abstinence rate
at 52-weeks; % (SD)
Product compliance
Cost of therapy

200 mg once daily
12 weeks

66%
$383.52

Tashkin D et al

Drug cost

$191.76

Rxprice.com

Physician visit cost
NRT
(patch)114,116,117,120,121,122

$260

Dose

Duration
Smoking abstinence rate
at 52-weeks; % (SD)
Product compliance

15.7 (3.01)

Step 1: 21 mg patch/day
for two weeks; step 2:
14 mg patch/day for two
weeks; step 3: 7 mg
patch/day for two weeks
8 weeks

Healthcare blue book

Fiore MC et al., 2008

Fiore MC et al., 2008
Taylor et al., Silagy C et al.,
15.5 (0.79) Gonzales et al., Woolacott NF
et al.
78%
Tonnesen P et al

Cost of therapy
E-cigarettes

Taylor et al., Gonzales et al.,
Jorenby DE et al.

$155

Drugstore.com

123,124

Dose
Duration
Smoking abstinence rate
at 52-weeks; % (SD)
Product compliance

16 mg nicotine ecigarettes from one
week before until 12
weeks after quit day
12 weeks
21.08(16.03)
78%

Cost of therapy

$478.2

Bullen C et al.
Bullen C et al.
Literature review
Bullen C et al.
http://ecigarettereviewed.com/
v2-cigs-e-cigarette-savingscalculator/

No cessation116
Smoking abstinence rate
at 52-weeks; % (SD)

5.0 (0.50)

120

Taylor et al.

Step 7: Determining disease related costs
The COPD disease related costs for current smokers were calculated by estimating the
average per patient costs to treat COPD. As we were interested in learning about
economic healthcare impact that these therapies will have from a societal perspective,
both direct and indirect costs were calculated from the nationalized data. Results from
the chapter 4 were used in developing the budget impact model. The healthcare costs
used in the BI model were the incremental cost among current smokers with COPD in
comparison to non-smokers. The cost estimates used were total costs, as well the costs
by gender and by different age groups. Table 18 below provides the cost estimates that
went into the BI model analysis.
Table 18: Incremental cost among current smokers with COPD; estimates by
total, by gender and by different age groups.
COPD disease related
costs

Incremental cost

Total incremental cost among
current smokers with COPD
Total incremental cost among
current smokers with COPD
by gender
Male
Female
Total incremental cost among
current smokers with COPD
by age group
18-44
45-64
65 & above
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$1,811

$1,687
$1,915

$1,353
$1,878
$2,113

Step 8: Outcome evaluation
BI outcomes evaluated were the total cost offset or cost savings associated with e-cigs
use in comparison to smoking cessation alternatives and no cessation over the period
of 1-year and 5-years. Further, we also evaluated the impact of age and gender on the
BI model outcomes. Hence, three separate models were built in order to study the
impact of e-cigs adoption among current smokers with COPD in overall population, by
different age groups and by gender. For each year, the economic impact of using e-cigs
as a smoking cessation tool over other available alternatives were obtained by
multiplying the estimated number of COPD patients who effectively stopped smoking for
the entire 1-year period by per person incremental healthcare costs which included
both; drug therapy cost and COPD healthcare cost.
Step 9: Model assumptions
BI model for this study had the following model assumptions:
 The final targeted population who have tried quitting smoking in the past represents
the current US smoking population who wants to actively quit smoking
 Smoking cessation rates reflects the successful quit attempt amongst users who were
adherent to the therapy for at least 1 year and were able to follow up till end of the study
 We assumed that smoking cessation rates for all of the pharmacotherapies/device
observed in the controlled clinical trials were very similar to the real world scenario
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 We also assumed that smoking cessation rates among COPD patient population
were nearly similar to the smoking cessation rates observed in general healthy
population in controlled clinical trials who wanted to quit smoking actively
 All e-cig users who were allotted cigalikes for quitting smoking contained nicotine
 Age and gender specific smoking cessation rates were assumed to remain constant
throughout the 1-year period
Step 10: Uncertainty analysis
In order to test for uncertainty associated with the model parameter estimates and
model assumptions, one-way sensitivity analysis was performed on the following model
parameters with the following ranges:


COPD incidence rate (3% - 6%)



COPD prevalence rate (3.1% - 12.3%)



Percentages of current smokers among COPD (22.22% - 44.55%)



Population who wants to quit smoking (51.47% - 75.35%)



E-cigs efficacy (11.94% - 30.21%)



E-cigs product cost ($216 - $740)



Product compliance for E-cigs (± 20%)



Product compliance for drug therapies (± 20%)



Product compliance for NRT’s (± 20%)



One additional physician visit for drug therapies ($260)



COPD healthcare cost ($345.47 - $3,277.93)
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Relapse rate (5% - 17%)

Lower bound and upper bound values were considered for all the parameters in the
sensitivity analysis. For those parameters whose upper bounds and lower bounds
weren’t available, we changed the parameter estimates within the range of ± 20%.
5.2: Results
Aim 3A: To estimate the 1-year and accumulated 5-year total healthcare cost
savings associated with E-cigarettes (e-cigs) use in comparison to smoking
cessation therapies among current smokers with COPD in the US
The total targeted population for the first year of the BI model was estimated to be
3,460,976 and represented the individuals residing in the US, been diagnosed with
COPD, currently smoking cigarettes and have tried quitting smoking in the past. This
estimate represents the population who wants to quit smoking actively and are
interested in trying any of the smoking cessation alternatives. The total number of
successful quitters for all of the smoking cessation alternatives for the first year and the
fifth year of the BI model were estimated to be around 497,446 and 316,325
respectively. The accumulated 5-year success in achieving smoking abstinence were
estimated to be 3,757,549 (20% of the total targeted population) for all of smoking
cessation alternatives. The number of successful quitters were higher among e-cig
users in comparison to those using drug therapies, NRT’s and no cessation. The
number of successful quitters among e-cig users were higher by 19,835 for the 1st year,
76,380 for 2nd year, 63,571 for 3rd year, 122,910 for 4th year, and 34,645 for 5th year
in comparison to drug therapies and NRT's. The accumulated 5-year success in
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achieving smoking abstinence among e-cig users were higher by 317,342 in
comparison to drug therapies and NRT's. Total number of population who failed to quit
smoking among e-cig users were lower by 404,452 and by 161,339 during the 1 st year
and 5th year of the BI model respectively in comparison to drug therapies and NRT's.
The accumulated 5-year smoking cessation failure among e-cig users were lower by
1,668,389 in comparison to drug therapies and NRT's. The adoption of e-cigs as a
smoking cessation tool among COPD population over drug therapies and NRT’s can
lead to the total healthcare loss of $20.10 million for the 1 st year, savings of $17.85
million for the 2nd year, loss of $17.33 million for the 3rd year, savings of $44.36 million
for the 4th year and savings of $12.92 million for the 5 th year. The accumulated 5-year
total healthcare cost savings associated with the use of e-cigs over drug therapies and
NRT's was estimated to be around $37.71 million. The adoption of e-cigs as a smoking
cessation tool in comparison to no cessation alternative among COPD population can
lead to the total healthcare cost savings of $20.10 million for the 1 st year, $45.44 million
for the 2nd year, $5.11 million for the 3rd year, and $30.06 million for the 5 th year. The
accumulated 5-year total healthcare cost savings associated with the use of e-cigs in
comparison to no cessation alternative were estimated to be around $76.36 million. The
BI model estimates for the adoption of e-cigs as a smoking cessation tool over other
alternatives among COPD individuals in the US are provided in the table 19 as below.
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Table 19: Budget Impact model for adopting e-cigs as a smoking cessation tool among current smokers with
COPD; cost savings estimates over the period of 5-year

BI model parameters

First year

Second year

Third year

Fourth year

Fifth year

General US population
247,773,709
Prevalence of COPD
15,461,079
Incident COPD population
10,454,068
9,983,635
9,534,371
Percentage of current smokers
5,462,399
3,693,422
3,527,218
3,368,493
among individuals with COPD
Percentage of current smokers with
COPD who have tried quitting
3,460,976
2,340,152
2,234,845
2,134,277
smoking in past one year
Total target population
3,460,976
5,353,426
6,923,261
8,198,003
Market share estimates for smoking cessation alternatives
Drug therapies
472,077.16
428,274.12
741,481.25
793,566.78
NRT’s
1,415,885.38
2,355,507.67
2,967,309.67
3,438,242.85
E-cigs
1,573,013.70
2,569,644.73
3,214,470.09
3,967,014.11
No Cessation
3,460,976.24
5,353,426.51
6,923,261.02
8,198,003.95
Number of successful quitters per year
Drug therapies
67,625
61,350
106,217
113,678
NRT’s
171,180
284,780
358,747
415,683
E-cigs
258,641
422,511
528,536
652,272
No Cessation
173,048
267,671
346,163
409,900
Differences in the number of successful quitters between e-cig users and other smoking cessation alternatives
19,835
76,380
63,571
122,910
Accumulated success
19,835
96,215
159,786
282,697
Number of patients who failed to quit smoking per year
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9,105,324
3,216,911
2,038,235
2,197,388
188,316
941,800
1,067,271
2,197,388
26,976
113,863
175,485
109,869
34,645
317,342

Drug therapy
404,452
366,923
635,264
679,888
NRTs
1,244,704
2,070,726
2,608,561
3,022,559
E-cigs
1,314,372
2,147,133
2,685,934
3,314,741
No cessation
3,287,927
5,085,755
6,577,097
7,788,103
Differences in the number of failures between e-cig users and other smoking cessation alternatives
(334,784)
(290,517)
(557,891)
(387,705)
Accumulated failures
(625,301)
(1,183,193)
(1,570,899)
Total healthcare costs savings associated with E-cigs use over other alternatives
($20,101,088)
$17,856,027
($17,330,091)
$44,362,032
Accumulated total healthcare cost savings over other alternatives
($2,245,060)
($19,575,151)
$24,786,880
Total healthcare costs savings associated with E-cigs use over no cessation
$20,101,088
$45,441,236
$5,111,387
($4,257,479)
Accumulated total healthcare costs savings associated with E-cigs use over no cessation
$76,766,835
$50,552,623
$46,295,144
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161,339
827,936
891,786
2,087,519
(97,490)
(1,668,389)
$12,923,846
$37,710,727
$30,069,115
$76,364,260

Aim 3B: To estimate the 1-year and accumulated 5-year total healthcare cost
savings by gender associated with e-cigs use in comparison to smoking
cessation therapies among current smokers with COPD in the US
Two separate BI models were developed, one representing males and other
representing females, in order to explore the differences in economic impact by gender
for adopting e-cigs among current smokers with COPD.
For the BI model representing males, the total targeted population for the first year of
the model was estimated to be 1,436,258. The number of successful quitters were
higher among e-cig users in comparison to those using drug therapies, NRT’s and no
cessation. The number of successful quitters among e-cig users were higher by 8,231
for the 1st year, 31,717 for 2nd year, 26,302 for 3rd year, 50,696 for 4th year, and
14,119 for 5th year in comparison to drug therapies and NRT's. The accumulated 5-year
success in achieving smoking abstinence among e-cig users were higher by 131,067 in
comparison to drug therapies and NRT's. Total number of population who failed to quit
smoking among e-cig users were lower by 138,931 and by 39,731 during the 1 st year
and 5th year of the BI model respectively in comparison to drug therapies and NRT's.
The accumulated 5-year smoking cessation failure among e-cig users were lower by
690,050 in comparison to drug therapies and NRT's. The adoption of e-cigs as a
smoking cessation tool among COPD population over drug therapies and NRT’s can
lead to the total healthcare loss of $9.36 million for the 1 st year, savings of $3.48 million
for the 2nd year, loss of $10.43 million for the 3 rd year, savings of $12 million for the 4 th
year and savings of $3.51 million for the 5 th year. The accumulated 5-year total
healthcare cost loss associated with the use of e-cigs over drug therapies and NRT's
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was estimated to be around $775,442 million. The BI model estimates for the adoption
of e-cigs as a smoking cessation tool over other alternatives among COPD males in the
US are provided in the table 20 as below.
For the BI model representing females, the total targeted population for the first year of
the model was estimated to be 2,028,576. The number of successful quitters were
higher among e-cig users in comparison to those using drug therapies, NRT’s and no
cessation. The number of successful quitters among e-cig users were higher by 11,626
for the 1st year, 44,798 for 2nd year, 37,150 for 3rd year, 71,603 for 4th year, and
19,942 for 5th year in comparison to drug therapies and NRT's. The accumulated 5-year
success in achieving smoking abstinence among e-cig users were higher by 185,120 in
comparison to drug therapies and NRT's. Total number of population who failed to quit
smoking among e-cig users were lower by 196,226 and by 56,116 during the 1 st year
and 5th year of the BI model respectively in comparison to drug therapies and NRT's.
The accumulated 5-year smoking cessation failure among e-cig users were lower by
974,629 in comparison to drug therapies and NRT's. The adoption of e-cigs as a
smoking cessation tool among COPD population over drug therapies and NRT’s can
lead to the total healthcare loss of $10.57 million for the 1 st year, savings of $15.13
million for the 2nd year, loss of $6.25 million for the 3 rd year, savings of $33.30 million for
the 4th year and savings of $9.51 million for the 5 th year. The accumulated 5-year total
healthcare cost savings associated with the use of e-cigs over drug therapies and
NRT's was estimated to be around $41.12 million. The BI model estimates for the
adoption of e-cigs as a smoking cessation tool over other alternatives among COPD
females in the US are provided in the table 21 as below.
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The BI model estimates comparison among males and females informs that adoption of
e-cigs as a smoking cessation tool can lead to higher success and lower failure rates in
quitting smoking in comparison to drug therapies and NRT's. However, adoption of e-cig
devices over the period of 5-year can lead to the loss in total healthcare among males,
and can lead to substantial healthcare savings or gains among females.
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Table 20: Budget Impact model for adopting e-cigs as a smoking cessation tool among males, currently smoking
and with COPD; cost savings estimates over the period of 5-year
BI model parameters for Males

First year

Second year

Total target population

Third year

Fourth year

Fifth year

1,436,258.31
Market share estimates for smoking cessation alternatives
Drug therapy
195,905.63
177,847.02
306,792.22
327,318.55
76,746.92
NRTs
587,573.28
978,158.61
1,227,741.80
1,418,154.97
383,824.16
E-cigs
652,779.40
1,067,082.12
1,330,005.87
1,636,254.62
434,958.92
Number of successful quitters per year
Drug therapy
28,063.48
25,476.59
43,947.99
46,888.38
10,994.00
NRTs
71,037.61
118,259.38
148,433.98
171,454.94
46,404.34
E-cigs
107,332.60
175,453.91
218,684.89
269,039.53
71,517.69
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives
8,231
31,717
26,302
50,696
14,119
Accumulated success
39,949
66,252
116,948
131,067
Number of patients who failed to quit smoking per year
Drug therapy
167,842.15
152,370.43
262,844.24
280,430.17
65,752.92
NRTs
516,535.67
859,899.23
1,079,307.81
1,246,700.03
337,419.82
E-cigs
545,446.80
891,628.21
1,111,320.99
1,367,215.09
363,441.24
Difference in the number of failures between e-cig users and other smoking cessation alternatives
(138,931)
(120,641)
(230,831)
(159,915)
(39,731)
Accumulated failures
(259,572)
(490,403)
(650,318)
(690,050)
Average total healthcare cost savings associated with E-cigs use over other alternatives
($9,361,802.32)
$3,484,199.82 ($10,430,121) $12,015,056.38
$3,517,224.85
Accumulated total healthcare cost savings over other alternatives
($5,877,602.50) ($16,307,723)
($4,292,667)
($775,442.31)
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Table 21: Budget Impact model for adopting e-cigs as a smoking cessation tool among females, currently
smoking and with COPD; cost savings estimates over the period of 5-year
BI model parameters for Females

First year

Second year

Total target population

Third year

Fourth year

Fifth year

2,028,576
Market share estimates for smoking cessation alternatives
Drug therapy
276,697.80
251,191.75
433,314.40
462,305.86
108,397.62
NRTs
829,890.54
1,381,554.62
1,734,066.78
2,003,007.00
542,114.58
E-cigs
921,987.90
1,507,150.49
1,878,504.91
2,311,051.71
614,337.49
Number of successful quitters per year
Drug therapy
39,636.96
35,983.22
62,072.29
66,225.31
15,527.96
NRTs
100,333.77
167,029.95
209,648.67
242,163.55
65,541.65
E-cigs
151,596.94
247,811.71
308,871.29
379,992.37
101,011.83
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives
11,626
44,798
37,150
71,603
19,942
Accumulated success
56,424
93,575
165,178
185,120
Number of patients who failed to quit smoking per year
Drug therapy
237,060.84
215,208.53
371,242.11
396,080.55
92,869.66
NRTs
729,556.77
1,214,524.66
1,524,418.11
1,760,843.46
476,572.92
E-cigs
770,390.96
1,259,338.78
1,569,633.62
1,931,059.35
513,325.67
Difference in the number of failures between e-cig users and other smoking cessation alternatives
(196,226)
(170,394)
(326,026)
(225,864)
(56,116)
Accumulated failures
(366,621)
(692,647)
(918,512)
(974,629)
Average total healthcare cost savings associated with E-cigs use over other alternatives
($10,571,121.58) $15,138,030.43 ($6,258,886.26) $33,300,289.34
$9,515,842.36
Accumulated total healthcare cost savings over other alternatives
$4,566,908.85 ($1,691,977.41) $31,608,311.93 $41,124,154.29
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Aim 3C: To estimate the 1-year and accumulated 5-year total healthcare cost
savings by different age groups associated with e-cigs use in comparison to
smoking cessation therapies among current smokers with COPD in the US
BI model was developed to estimate the economic impact of adopting e-cigs within
different age groups; 18-44 years, 45-64 years, 65 & above. The total targeted
population for the first year BI model were estimated to be 904,593 among individuals
with 18-44 years, while for the individuals between 45-64 years and 65 & above, it was
estimated to be around 1,902,765, and 658,516 respectively. The number of successful
quitters were higher among e-cig users in comparison to those using drug therapies and
NRT’s. The number of successful quitters during the 1st year of BI model were higher
by 5,184 among individuals with 18-44 years, by 10,905 among individuals between 4564 years and by 3,774 among individuals with age 65 years and above. The number of
successful quitters during the 5th year of BI model were higher by 7,875 among
individuals with 18-44 years, by 16,566 among individuals between 45-64 years and by
6,182 among individuals with age 65 years and above. The accumulated 5-year
success in quitting smoking among e-cig users in comparison to drug therapies and
NRT's were higher by 79,303 among individuals with 18-44 years, by 166,811 among
individuals between 45-64 years and by 93,597 among individuals with age 65 years
and above. The success in quitting were higher among 45-64 years of age group in
comparison to individuals between 18 and 44 years and 65 & above years. Further, the
number of individuals failing to quit smoking per year among e-cig users were lower in
comparison to drug therapies and NRT's. The accumulated 5-year failure in quitting
smoking among e-cig users were lower by 421,786 among individuals with 18-44 years,
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by 887,206 among individuals between 45-64 years and by 452,652 among individuals
with age 65 years and above. The failure rates were lower among individuals between
45-64 years in comparison to individuals with 18-44 years and 65 & above age group.
The adoption of e-cigs as a smoking cessation tool among COPD individuals between
18 and 44 years of age group can lead to the loss of $7.6 million for the 1 st year, $4.41
million for the 2nd year, $11.74 million for 3 rd year, $2.9 million for 4th year, and $0.66
million for the 5th year. The adoption of e-cigs as a smoking cessation tool among
COPD individuals between 45 and 64 years of age group can lead to the loss of $10.31
million for the 1st year, savings of $12.49 million for the 2 nd year, loss of $6.92 million for
3rd year, savings of $27.46 million for 4 th year, and savings of $7.31 million for the 5 th
year. The adoption of e-cigs as a smoking cessation tool among COPD individuals with
age 65 & above can lead to the loss of $2.68 million for the 1 st year, savings of $7.69
million for the 2nd year, savings of $0.52 million for 3 rd year, savings of $34 million for 4 th
year, and savings of $4.17 million for the 5 th year. The accumulated 5-year total
healthcare cost savings associated with e-cigs use in comparison to drug therapies and
NRT's were found to be $34.76 million and $38 million among COPD individuals
between 45-64 years and 65 & above respectively. Adoption of e-cigs among
individuals with 18-44 years of age group would lead to a loss of $3.61 million in total
healthcare costs over the period of 5-years. BI model estimates among different age
groups for the adoption of e-cigs as a smoking cessation tool in presence of other
smoking cessation alternatives are given in table 22 as below.
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Table 22: Budget Impact model for adopting e-cigs as a smoking cessation tool among different age groups,
currently smoking and with COPD; cost savings estimates over the period of 5-year
BI model parameters
First year
Second year
Third year
Fourth year
Fifth year
by different age groups
Total target population
18-44
904,593.19
45-64
1,902,765.00
65 & above
658,516.12
Number of patients quitting smoking per year
Drug therapies
18-44
17,675.12
15,829.93
26,860.34
28,171.56
6,132.52
45-64
37,178.70
33,297.43
56,499.33
59,257.42
12,899.44
65 & above
12,866.94
11,523.70
29,248.46
47,899.48
4,813.83
NRT’s
18-44
44,741.35
73,480.69
90,720.58
103,013.86
25,884.64
45-64
94,111.12
154,562.84
190,826.04
216,684.32
54,447.00
65 & above
32,570.33
53,491.69
98,786.44
175,152.18
20,318.58
E-cigs
18-44
67,600.89
109,018.63
133,656.85
161,644.80
39,893.02
45-64
142,194.98
229,315.05
281,140.28
340,011.49
83,912.91
65 & above
49,211.38
79,362.22
145,540.13
274,841.09
31,314.70
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives
18-44
5,184
19,708
16,075
30,459
7,875
45-64
10,905
41,454
33,814
64,069
16,566
65 & above
3,774
14,346
17,505
51,789
6,182
Number of patients failing to quit smoking per year
Drug therapies
18-44
105,711
94,675
160,646
168,488
36,677
45-64
222,358
199,145
337,911
354,406
77,149
65 & above
76,954
68,920
174,929
286,477
28,790
NRT’s
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18-44
325,327
534,300
659,656
749,044
45-64
684,310
1,123,872
1,387,553
1,575,576
65 & above
236,828
388,954
718,305
1,273,583
E-cigs
18-44
343,536
554,014
679,222
821,452
45-64
722,611
1,165,341
1,428,709
1,727,883
65 & above
250,084
403,305
739,611
1,396,697
Difference in the number of failures between e-cig users and other smoking cessation alternatives
18-44
(87,502)
(74,960)
(141,080)
(96,080)
45-64
(184,056)
(157,676)
(296,755)
(202,100)
65 & above
(63,699)
(54,569)
(153,623)
(163,363)
Total healthcare cost savings with E-cigs use over other alternatives
18-44
(7,626,718.21)
(4,413,047.67)
(11,740,412.76)
(2,947,552.83)
45-64
(10,312,835.69)
12,497,723.17
(6,928,998.49)
27,462,219.50
65 & above
(2,682,305.10)
7,696,333.29
526,214.66
34,367,464.79
Accumulated total healthcare cost savings with E-cigs use over other alternatives
18-44
(4,413,047.67)
(11,740,412.76)
(2,947,552.83)
45-64
12,497,723.17
(6,928,998.49)
27,462,219.50
65 & above
7,696,333.29
526,214.66
34,367,464.79
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188,214
395,900
147,742
202,729
426,431
159,136
(22,162)
(46,617)
(17,396)
(666,804.14)
7,301,435.56
4,177,410.13
(3,614,356.97)
34,763,655.07
38,544,874.92

One-way sensitivity analysis results:
One-way sensitivity analyses were performed on several of the model parameters.
Table 23 below represents the sensitivity analysis estimates in terms of lower bound
and upper bound for the parameters varied. The results indicate that e-cigs efficacy was
the parameter with the highest influence on the BI model results, followed by cost for ecigs devices, product compliance for e-cigs, COPD healthcare cost and NRT’s product
compliance. The parameters with minimal influence on the BI model results were drug
therapies product compliance, additional physician visit cost, COPD incidence rate,
prevalence of smoking among COPD individuals, population who wants to quit smoking,
COPD prevalence rate and smoking relapse rate. A tornado diagram (Figure 12) was
developed to display the one-way sensitivity analysis estimates for the varied
parameters from most sensitive (bottom) to least sensitive (upper) parameters. The
sensitive variable was changed at an uncertain value while all other variables were held
constant at their baseline values. Green bars in figure 12 represent lower bound values,
while blue bars represent upper bound values.
Table 23: One-way sensitivity analysis results for the BI model
5-year accumulated total healthcare cost savings among e-cig users in
comparison to drug therapies and NRT’s among COPD individuals in the US
Parameters varied
One-way
Sensitivity analysis
sensitivity analysis
results (in millions)
range
Lower
Upper
Lower
Upper
bound bound
bound
bound
E-cigs efficacy
11.94
30.21
-$1,173.00 $1,178.00
E-cigs cost
216
740
$572.00
-$496
E-cigs product compliance
63
93
-$490.00
$552
COPD healthcare cost
345
3277
$427.00
$503
NRT's product compliance
63
93
$470.00
-$387
Drug therapy product compliance
60
90
$128.00
$53
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One additional physician visit for drug
therapy
COPD incidence rate
Prevalence of smoking among COPD
Population who wants to quit
smoking
COPD prevalence rate
Smoking relapse rate

899.8

--

$148

3
22.22
51.47

6
44.55
75.35

$25.00
$24.00
$31.00

$50
$48
$45

3.1
5

12.3
17

$41.00
$37.00

$31
$39

Figure 12: Tornado chart depicting the 5-year accumulated total healthcare cost
savings among e-cig users in comparison to drug therapies and NRT’s among
COPD individuals in the US. (Base case: $37.71 million)
Smoking relapse rate

Lower bound

COPD prevalence rate

Upper bound

Population who wants to quit smoking
Prevalence of smoking among COPD

COPD incidence rate
One additional physician visit for drug
therapy
Drug therapy product compliance
NRT's product compliance

COPD healthcare cost
E-cigs product compliance
E-cigs cost

E-cigs efficacy
-$1,500.00 -$1,000.00 -$500.00

$0.00

$500.00 $1,000.00 $1,500.00

5-year accumulated budgetary impact for adopting e-cigs over other smoking
cessation alternatives among current smokers with COPD
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5.3: Discussion
This study analyzed the economic impact of adopting e-cigarettes as a smoking
cessation tool among COPD patient population. For the first year of our BI model, we
identified targeted population of around 3.5 million individuals who were current
smokers, have tried quitting smoking in the past and have been diagnosed with COPD
in the US. Total number of patients who were able to quit smoking successfully using ecigs over the period of 5-year were around 2 million and the rate of success was higher
by 317,342 individuals in comparison to drug therapies and NRT’s. Adoption of e-cig
device for quitting smoking over the period of 5-year in the current US healthcare
system can lead to the cost savings of $37.71 million in comparison to drug therapies
and NRT’s, while it can lead to the cost savings of $76.36 million in comparison to no
cessation option.
Adoption of this device among women can have a positive impact on the healthcare
budget as the total healthcare cost savings associated with e-cigs use in comparison to
other smoking cessation options over the period of 5-year was $41.12 million. Among
men, adoption of e-cigs device may have a negative impact on the healthcare budget as
providers will have to spend additional $775,442 dollars to achieve success in quitting
with the help of e-cigs. The differences in healthcare savings among gender may be
due to the differences in estimates by gender for the prevalence of COPD, for current
smoking activity and for those trying to quit smoking in the past. According to the
BRFSS estimates for this study, the prevalence of COPD was higher by 14% among
women in comparison to men. Similarly, the prevalence estimates for current smokers
with COPD were higher by 12% among women in comparison to men. Further,
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prevalence estimates for individuals having tried quitting smoking in the past were
higher by 17% among women in comparison to men. In addition, research studies have
found that over the past few years, prevalence for COPD among women have
surpassed men. Further, rates of hospitalizations and mortality due to COPD, and
tobacco use have increased in past few years among women in comparison to men.125
Healthcare cost estimates among current smokers with COPD from the MEPS data
analysis were found to be higher among women in comparison to men. The estimates
were higher by $228 among women in comparison to men.
Further, BI model estimates among COPD current smokers with different age groups
were different. The number of successful quitters associated with e-cigs use in
comparison to other smoking cessation alternatives were found higher among
individuals between 45-64 years of age in comparison to individuals between 18-44
years of age and with age 65 and above. Further, the number of failures associated with
e-cigs use in comparison to other smoking cessation alternatives were found lower
among individuals between 45-64 years of age in comparison to individuals between
18-44 years of age and with age 65 and above. The adoption of e-cigs among all
different age groups for the first year was found to have a negative impact of the
budget, while for the second year; it was found to have a positive impact on the
healthcare budget among individuals with age 45 and above. Adoption of these devices
among individuals with age 65 and above will have a positive impact on the budget and
will lead to the healthcare cost savings of $38.0 million. Similarly, adoption of these
devices among individuals between age 45 and 64 will have a positive impact on the
budget and will lead to the healthcare cost savings of $34.0 million. The positive impact
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on healthcare budget among individuals with age 45 and above could be due the
differences in the prevalence and incidence estimates for COPD, for current smoking,
and for those trying to quit smoking in the past. In addition, the healthcare costs among
current smokers with COPD were higher among individuals with age 45 and above in
comparison to individuals between age 18 and 44 years.
This study possess several strengths. It is the first to assess the economic impact of ecigs among COPD current smoking population. We compared e-cigs with the highly
recommended and highly utilized pharmacotherapies such as Varenicline, Bupropion,
and NRT’s. Also, the results from this study are generalizable, as the epidemiological
cohort model was developed to identify the targeted population. The cohort for the first
year BI model included the COPD prevalent population analyzed using BRFSS
database, while the cohort starting from the second year included incident population
where the estimates came from the survey report conducted by the CDC. Further, a
flexible BI model was developed for the purpose of creating estimates that can include
several combinations of social service, healthcare, and other costs, contingent on the
perspective.
This study has a few limitations. First, because of the nature of the study design, BI
model results were based on several assumptions. Because of the lack of randomized
controlled trials for e-cigs in cessation among COPD patient population, all our smoking
cessation estimates came from the general population, which could be the mix of
healthy and unhealthy individuals. However, estimates for the targeted cohort were
generalizable as they were analyzed using nationally representative sample from
BRFSS data. Second, all the data estimates for the BI model were from the publicly
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available information. Information on market share for smoking cessation, smoking
cessation product prices and efficacy, incidence rates for COPD, relapse rate after
quitting smoking were obtained from the published resources that were available online.
However, to test uncertainty associated with these parameters and to estimate their
impact on the BI model results, we conducted one-way sensitivity analysis on these
parameters. Third, the BI model was developed only for a short-term period of 5 years
due to the limitations associated with the data available for use. Fourth, smoking
cessation outcomes evaluated were limited only up to the period of 1-year or 52-weeks.
Evaluation of smoking abstinence for long-term will give a complete idea on the impact
of adoption of e-cigs for smoking cessation into the current healthcare system. Finally,
side effects associated with the use of e-cigs or other smoking cessation
pharmacotherapies were not included in BI model estimates. Calculating the economic
costs associated with the side effects of these smoking cessation options may have a
different impact on the estimates for BI.

142

Chapter 6: Conclusions and Future research
Conclusions:
Our study estimated the economic impact of adopting e-cigarettes as a smoking
cessation tool among current smokers with COPD. We conclude that implementing ecigs as a harm reduction tool among smokers with COPD can help them achieve
smoking abstinence with a positive impact on the US healthcare budget. Adoption of
these devices over the period of 5-year can lead to total healthcare costs savings of
$37.71 million in comparison to other smoking cessation options such as Varenicline,
Bupropion and NRT’s. Specifically, these devices will have higher healthcare cost
savings among women and among individuals with age 65 & above. Overall, our study
results indicate that use of these devices as a smoking cessation tool among diseased
population such as COPD will have positive impact on patients and will be beneficial to
the US healthcare budget.
COPD is a progressive lung disease that possess a huge economic burden to the
society. Tobacco smoking plays a key role to COPD development. The best way to
avoid this disease development and reduce healthcare costs is to quit smoking. With
the increase in awareness of e-cigs, these devices are being used an alternative to
cigarette smoking or to help smokers in reducing or quitting cigarettes consumption.
This study estimated the prevalence of current and ever e-cig users among COPD
patient population using nationally representative US adult population. Prevalence of ecigs use was found to be higher among disease adult population in comparison to
general healthy adult population. Popularity of electronic cigarettes have not just
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increased in general population, but its demand and usage have also increased
significantly among COPD disease population. Our results also suggest that among
individuals with COPD, current e-cigs use was found to be higher among currently
smoking population and among those who tried quitting the use of tobacco in past.
These might suggests that these devices were either being tried as an alternative over
other smoking cessation tools or were being used as a replacement to conventional
cigarette smoking. However, evidences related to safety and efficacy for these devices
still remains unknown, especially among COPD patient population.
Future research:
Based on the published evidences and nationally representative sample, this study
supports the use of e-cigs in smoking cessation among COPD patient population.
However, due to high uncertainty associated with the short- and long-term safety of
these devices, we weren’t able to include them in our study. Hence, future studies are
needed that can incorporate side-effects and safety associated with the use of these
devices. Further, randomized controlled trials and cohort studies have evaluated the
effectiveness of e-cigs for smoking cessation among healthy adult population. Research
studies are needed that can evaluate the effectiveness of these devices among disease
population such as COPD where quitting tobacco use is highly recommended
alternative. Having clarity on side-effects, long-term and short-term safety and
effectiveness of e-cigs use among COPD patient population will give more precise
estimates for the adoption of these devices in US healthcare system. Further, these
study assumed the use and effect of first generation e-cigs device among COPD
individuals. Future studies are warranted that can compare the economic impact of first
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generation with second, third and fourth generation e-cig devices. Additionally, the
effect of FDA regulations on the perception and uptake of e-cigs device among
diseased population are needed to help payers, clinicians and patients make informed
decisions.
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